0001354488-16-007347.txt : 20160512 0001354488-16-007347.hdr.sgml : 20160512 20160512145258 ACCESSION NUMBER: 0001354488-16-007347 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 26 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160512 DATE AS OF CHANGE: 20160512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MYMETICS CORP CENTRAL INDEX KEY: 0000927761 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 251741849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-25132 FILM NUMBER: 161643248 BUSINESS ADDRESS: STREET 1: EUROPEAN EXECUTIVE OFFICE STREET 2: 4, ROUTE DE LA CORNICHE CITY: EPALINGES STATE: V8 ZIP: CH-1066 BUSINESS PHONE: 011-41-21-653-45-35 MAIL ADDRESS: STREET 1: EUROPEAN EXECUTIVE OFFICE STREET 2: 4, ROUTE DE LA CORNICHE CITY: EPALINGES STATE: V8 ZIP: CH-1066 FORMER COMPANY: FORMER CONFORMED NAME: ICHOR CORP DATE OF NAME CHANGE: 19970407 FORMER COMPANY: FORMER CONFORMED NAME: PDG REMEDIATION INC DATE OF NAME CHANGE: 19940801 10-Q 1 mymx_10q.htm QUARTERLY REPORT mymx_10q.htm


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2016

OR

o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE TRANSITION PERIOD FROM __________ TO _________

COMMISSION FILE NUMBER: 000-25132

MYMETICS CORPORATION
(Exact name of registrant as specified in its charter)
 
DELAWARE 
 
25-1741849
(State or other jurisdiction of incorporation or organization) 
 
(I.R.S. Employer Identification No.)
 
c/o Mymetics S.A.
Biopole
Route de la Corniche, 4
1066 Epalinges (Switzerland)
 
(Address of principal executive offices)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: 011 41 21 653 4535


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x          No o
             

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x         No o
  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “accelerated filer,” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 
1
 
 
 
 
Large Accelerated Filer o
 
Accelerated Filer o
 
         
 
Non-Accelerated Filer o
 
Smaller Reporting Company x
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   
Yes o         No x
                                             
Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date:
 
Class
 
Outstanding at May 12, 2016
Common Stock, $0.01 par value
 
303,757,622
 
 
 


 
2
 
 
 
PART I.    FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MYMETICS CORPORATION
CONSOLIDATED BALANCE SHEETS
 (UNAUDITED)
(In Thousands of Euros)


   
March 31,
   
December 31,
 
   
2016
   
2015
 
             
ASSETS
           
Current Assets
           
  Cash
 
E
1,997
   
E
2,381
 
  Receivables
   
112
     
218
 
  Prepaid expenses
   
87
     
66
 
      Total current assets
   
2,196
     
2,665
 
                 
  Property and equipment, net of accumulated depreciation of E324 at March 31, 2016
    and E314 at December 31,  2015
   
96
     
106
 
  In-process research and development
   
2,266
     
2,266
 
  Goodwill
   
6,671
     
6,671
 
   
E
11,229
   
E
11,708
 
                 
                 
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
               
Current Liabilities
               
  Accounts payable
 
E
145
   
E
416
 
  Deferred revenue from grants
   
828
     
1,014
 
  Convertible notes payable to related parties
   
43,719
     
43,170
 
      Total liabilities
   
44,692
     
44,600
 
                 
                 
Shareholders' Equity (Deficit)
               
  Common stock, U.S. $0.01 par value; 1,000,000,000 shares authorized; issued 303,757,622 at
    March 31, 2016 and at December 31, 2015
   
2,530
     
2,530
 
  Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none issued or outstanding
   
--
     
--
 
  Additional paid-in capital
   
34,343
     
34,315
 
  Accumulated deficit
   
(71,020
)
   
(70,427
)
  Accumulated other comprehensive income
   
684
     
690
 
     
(33,463
)
   
(32,892
)
   
E
11,229
   
E
11,708
 
 
The accompanying notes are an integral part of these financial statements.
 
 
3

 
 
MYMETICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
 (UNAUDITED)
(In Thousands of Euros, Except Per Share Data)

   
For The Three Months Ended
   
For The Three Months Ended
 
   
March 31, 2016
   
March 31, 2015
 
Revenue
           
Research and Development services
  E
219
   
E
610
 
Grants
   
186
     
52
 
     
405
     
662
 
Expenses
               
Research and development
   
109
     
367
 
General and administrative
   
343
     
393
 
Bank fee
   
1
     
1
 
Depreciation
   
10
     
10
 
Directors' fees
   
5
     
5
 
Foreign exchange and other
   
(92
)
   
193
 
     
376
     
969
 
Operating (Loss) Income
   
29
     
(307
)
                 
Interest expense
   
642
     
643
 
Loss before income tax (provision) benefit
   
(613
   
(950
                 
  Income tax (provision) benefit
   
20
     
(3
     
(593
)
   
(953
)
Other comprehensive loss
               
Foreign currency translation adjustment
   
(6
)
   
63
 
Comprehensive loss
 
E
(599
)
 
E
(890
)
                 
Basic earnings per share
 
E
0.00
   
E
0.00
 
Diluted earnings per share
 
E
0.00
   
E
0.00
 
 
The accompanying notes are an integral part of these financial statements.
 
 
4

 

MYMETICS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In Thousands of Euros)
 
   
For The Three Months Ended
   
For The Three Months Ended
 
   
March 31, 2016
   
March 31, 2015
 
Cash Flow from Operating Activities
           
Net Loss
 
$
(593
)
 
$
(953
)
Adjustments to reconcile net loss to net cash provided (used in) by operating activities
               
Depreciation
   
10
     
10
 
Stock compensation expense – options
   
28
     
15
 
Changes in operating assets and liabilities
               
Receivables
   
106
     
(21
Accrued interests on notes payable
   
549
     
877
 
Accounts payable
   
(271
   
112
 
Deferred revenue from grants
   
(186
)
       
Other
   
(21
   
(1
Net cash (used in) provided by operating activities
   
(378
)
   
39
 
                 
Cash Flows from Investing Activities
               
Purchase of property and equipment
   
--
     
(7
Net cash used in investing activities
   
--
     
(7
)
                 
  Effect on foreign exchange rate on cash
   
(6
)
   
63
 
Net change in cash
   
(384
   
95
 
                 
Cash, beginning of period
   
2,381
     
1,614
 
Cash, end of period
 
$
1,997
   
$
1,709
 
 
The accompanying notes are an integral part of these financial statements. 
 
 
5

 
 
MYMETICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2016
(UNAUDITED)
 

Note 1. The Company and Summary of Significant Accounting Policies
 
BASIS OF PRESENTATION

The amounts in the notes are shown in thousands of EURO rounded to the nearest thousand except for share and per share amounts.
 
The accompanying interim period consolidated financial statements of Mymetics Corporation (the "Company") set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2015.
 
The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three-month period ending March 31, 2016 were of a normal and recurring nature.
 
Mymetics Corporation (the "Company" or "Mymetics") was created for the purpose of engaging in vaccine research and development. Its main research efforts in the beginning have been concentrated in the prevention and treatment of the AIDS virus and malaria and has later expanded to other vaccines for infectious diseases since the acquisition of Bestewil Holding BV in April 2009. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. The Company has the following vaccines under development; (i) Herpes Simplex which is at the pre-clinical stage and currently on hold, (ii) intranasal influenza which has finished a clinical trial Phase I for which the Company is seeking partners (iii) Respiratory Syncytial Virus (RSV) which is at the pre-clinical stage, (iv) HIV-1 which has finished a Phase I and is currently in a repeat non-human primate study with the Texas Biomedical Research Institute, (v) malaria, which has finished a Phase Ib and a malaria transmission blocking vaccine which is in pre-clinical study with PATH-MVI and LMIV and (vi) two vaccine candidates that are currently in a discovery phase, one for Chikungunya and one for Zika.
 
As of March 31, 2016, the Company is in the pre-clinical testing of some of its vaccine candidates and a commercially viable product is not expected for several more years. However, the Company generates some revenue through the licensing of its RSV vaccine and from collaboration and grant agreements for R&D services. Management believes that the Company’s research and development activities will result in valuable intellectual property that can generate significant revenues in the future such as by licensing. Vaccines are one of the fastest growing markets in the pharmaceutical industry.
 
These consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced significant losses since inception resulting in an accumulated deficit of E71,020 at March 31, 2016. Further, the Company’s current liabilities exceed its current assets by E42,496 as of March 31, 2016, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts. These conditions raise substantial doubt about our ability to continue as a going concern.
  
PRINCIPLES OF CONSOLIDATION
 
The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated.

FOREIGN CURRENCY TRANSLATION

The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.
 
 
6

 

CASH

Cash deposits are occasionally in excess of insured amounts.

REVENUE RECOGNITION

  Exclusive Licenses
 
The deliverables under an exclusive license agreement generally include the exclusive license to the Company’s technology, and may also include deliverables related to research activities to be performed on behalf of the collaborative collaborator and the manufacture of preclinical or clinical materials for the collaborative collaborator.
 
Generally, exclusive license agreements contain non-refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) provide research services which are reimbursed at a contractually determined rate which includes margin for the Company, (ii) participate in a joint steering committee to monitor the progress of the research and development which will be reimbursed at a contractually determined rate which includes margin for the Company, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments at the time of commercialization until the later of expiration of the last to expire valid patent rights expire or 10 years after the first commercial sale. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements.  The Company does not directly control when any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments.  As a result, the Company cannot predict when it will recognize revenues in connection with any of the foregoing.
 
The Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, "Revenue Recognition—Multiple-Element Arrangements," and ASC Topic 605-28, "Revenue Recognition—Milestone Method," in accounting for these agreements.  In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the collaborator.  The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Factors considered in this determination include the research and manufacturing capabilities of the collaborator and the availability of technology research expertise in the general marketplace
 
RSV Corporation
 
    In December 2013, the Company entered into an agreement with RSV Corporation. The agreement provided RSV Corporation with an exclusive license to the Company’s RSV technology in order to develop and commercialize respiratory syncytial virus virosome vaccines. The Company received a US$5 million upfront payment in connection with the execution of the agreement and the Company was entitled to receive milestone payments potentially totaling $77 million plus royalties on product sales, if any. The Company also was entitled to receive payments for research and development activities performed on behalf of RSV Corporation. RSV Corporation was responsible for the development, manufacturing, and marketing of any products resulting from this agreement.
 
     In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the agreement. The significant deliverables were determined to be the RSV technology license and the research and development services including participation on the Joint Collaboration and Steering Committee (JCSC). The Company determined that the RSV technology license had standalone value from the research services. As a result, the research services were considered a separate unit of accounting. The estimated selling prices for these units of accounting were determined based on market conditions and entity-specific factors such as the terms of the collaborators’ previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company’s RSV technology, the Company’s pricing practices and pricing objectives, and the nature of the research services to be performed for RSV Corporation and market rates for similar services. The arrangement consideration was allocated to the deliverables based on the relative selling price method. The Company recognized license revenue when the exclusive license was delivered pursuant to the terms of the agreement which was upon execution of the agreement. The Company recognized research services revenue as the related services were delivered.
 
 
7

 
 
  On January 25, 2016 Mymetics received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious therapies. The LCA which was signed on December 27, 2013, between Bestewil Holding BV and RSVC will formally be terminated as of July 25, 2016.
 
Fixed price contracts and research and collaboration agreements
 
When the performance under a fixed price contract can be reasonably estimated, revenue for such a contract is recognized under the proportional performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses. If the performance under a fixed price contract cannot be reasonably estimated, the Company recognizes the revenue on a straight-line basis over the contract term.
 
TEXAS BIOMEDICAL RESEARCH INSTITUTE
 
 In September 2014, the Company entered into a material transfer agreement and fixed price contract with Texas Biomedical Research Institute. The agreement provides Texas Biomedical Research Institute the lead of a project which has been proposed to the Bill and Melinda Gates foundation with the objective to confirm previous results obtained in non-human primates with these virosome based HIV vaccine candidates. The Company has tested these different formulations of virosome based HIV vaccines candidates in preclinical non-human primate studies and in Phase I clinical settings. The Company produced and transferred to Texas Biomedical Research Institute the original material using the Company’s background IP. Results of the project with Texas Biomedical Research Institute was received in April 2016 (see note on subsequent events). The Company recognizes revenue under the proportional performance method.
 
PATH-MVI
 
In November 2014, the Company signed an agreement with PATH Malaria Vaccine Initiative (MVI) and the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), where Mymetics has developed and produced virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate which are based on two antigens provided by LMIV. The vaccine formulations were then tested in animal models. PATH MVI funded all activities under this project, which started in January 2015 and ended in January 2016. The Company has recognized revenue under the proportional performance method.
 
HORIZON 2020
 
In April 2015, the Company was selected to receive project grants with a total of E8.4 million. A total of E5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program and up to E3.1 million of funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The grant funds the evaluation, development and manufacturing scale-up of thermo-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Of the total amount, E3.4 million is directly attributable to Mymetics activities, with the remaining balance going to the consortium partners. The project duration is 42 months and started on May 4, 2015. In May 2015, the Company received a pre-payment from the two granting organizations for a total value of E1.5 million. The pre-payment has been recorded as a current liability and revenue has been recognized as services are delivered.
 
RECEIVABLES

Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. There was no allowance necessary at March 31, 2016 or December 31, 2015. The Company charges off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.

PROPERTY AND EQUIPMENT

Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.
 
 
8

 
 
IN-PROCESS RESEARCH AND DEVELOPMENT

In-process research and development (referred to as IPR&D) represents the estimated fair value assigned to research and development projects acquired in a purchased business combination that have not been completed at the date of acquisition and which have no alternative future use. IPR&D assets acquired in a business combination are capitalized as indefinite-lived intangible assets. These assets remain indefinite-lived until the completion or abandonment of the associated research and development efforts. During the periods prior to completion or abandonment, those acquired indefinite-lived assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired.

IMPAIRMENT OF LONG LIVED ASSETS

Long-lived assets, which include property and equipment, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income in the period that the impairment occurs.
 
GOODWILL

 Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis as of April 1 of each year, unless events or circumstances indicate impairment may have occurred before that time. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. After assessing qualitative factors, the Company must determine if further testing was necessary. If further testing was necessary, the Company would have performed a two-step impairment test for goodwill. The first step requires the Company to determine the fair value of each reporting unit. To the extent a reporting unit’s carrying amount exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company must perform a second more detailed impairment assessment. The second impairment assessment involves allocating the reporting unit’s fair value to all of its recognized and unrecognized assets and liabilities in order to determine the implied fair value of the reporting unit’s goodwill as of the assessment date. The implied fair value of the reporting unit’s goodwill is then compared to the carrying amount of goodwill to quantify an impairment charge as of the assessment date.
 
The Company has conducted its impairment testing as of April 1, of 2016 and 2015 of its goodwill recognized in connection to the acquisition of Bestewil. In conclusion of this impairment testing, the carrying amount of the reporting unit was lower than the estimated fair value of the reporting unit. As the fair value of the reporting unit is higher than the carrying amount, Step 2 of the goodwill impairment test did not need to be completed. As of March 31, 2016, management believes there are no indications of impairment.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred.
 
TAXES ON INCOME

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.
 
The Company reports a liability, if any, for unrecognized tax benefits resulting from uncertain income tax positions taken or expected to be taken in an income tax return. Estimated interest and penalties, if any, are recorded as a component of interest expense and other expense, respectively.
 
The Company has not recorded any liabilities for uncertain tax positions or any related interest and penalties at March 31, 2016 or December 31, 2015. The Company’s United States tax returns are open to audit for the years ended December 31, 2012 to 2015. The returns for the Swiss subsidiary, Mymetics S.A., are open to audit for the years ended December 31, 2010 to 2015. The returns for the Netherlands subsidiaries, Bestewil B.V. and Mymetics B.V., are open to audit for the year ended December 31, 2015.
 
 
9

 
 
EARNINGS PER SHARE

 Basic earnings per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. For the quarters ended March 31, 2016 and 2015, options and convertible debt were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred under the treasury stock method.

For the three months ended March 31, 2016, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 559,614,329 at March 31, 2016 includes 530,034,329 potential issuable shares related to convertible loans and 29,580,000 potential issuable shares related to outstanding not expired options granted to employees.

    For the three months ended March 31, 2015, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 494,877,358 at March 31, 2015 includes 474,027,358 potential issuable shares related to convertible loans, and 20,850,000 potential issuable shares related to outstanding stock options granted to employees.
  
PREFERRED STOCK

The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying dividend, conversion and voting rights. No preferred shares are issued or outstanding at March 31, 2016 or December 31, 2015.

STOCK-BASED COMPENSATION

 Compensation cost for all share-based payments is based on the estimated grant-date fair value. The Company amortizes stock compensation cost ratably over the requisite service period.

The issuance of common shares for services is recorded at the quoted price of the shares on the date the shares are issued. No shares were issued to individuals as fee for services rendered in the three months ended March 31, 2016 nor in the three months ended March 31, 2015.

Stock compensation expense amounted to E28 and E15 during the three months periods ended March 31, 2016 and 2015, respectively, and is included in the statement of operations within general and administrative expenses.
 
ESTIMATES

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

FAIR VALUE MEASUREMENTS

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:
 
 Level 1-   Quoted prices in active markets for identical assets or liabilities.
 Level 2-   Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
 Level 3-  
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
 
FAIR VALUES OF FINANCIAL INSTRUMENTS

The Company generally has the following financial instruments: cash, receivables, accounts payable, and notes payable. The carrying value of cash, receivables and accounts payable, approximates their fair value based on the short-term nature of these financial instruments. Management believes that it is not practicable to estimate the fair value of the notes payable due to the unique nature of these instruments.
 
 
10

 
 
CONCENTRATIONS

    The Company derived 54% and 94% of revenue from its relationship with one collaborative partner during the three month periods ended March 31, 2016 and March 31, 2015, respectively. Furthermore, that same collaborative partner accounted for 68% of the receivables balance at December 31, 2015 and 38% of the receivables balance at March 31, 2016.

RELATED PARTY TRANSACTIONS

An individual employed by the law firm that acts as the Company's general counsel is a member of the Board of Directors.  The Company incurred professional fees to the counsel's law firm totaling E5 and E7 for the period of three months ended March 31, 2016 and 2015, respectively.

NEW ACCOUNTING PRONOUNCEMENTS

     In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the fiscal and interim reporting periods beginning after December 15, 2017 using either of two methods:
 
(i)  
retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or

(ii)  
retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09.

  Management is currently evaluating the impact of the Company's pending adoption of ASU 2014-09 on its consolidated financial statements.
 
Note 2. Intangible Assets
 
Intangible assets consisted of in process research and development at March 31, 2016 and December 31, 2015.
 
Note 3. Debt Financing

Certain principal shareholders have granted the Company secured convertible notes (in accordance with the Uniform Commercial Code in the State of Delaware) and short term convertible notes, which have a total carrying value of E43,719 including interest due to date. Interest incurred on these notes since inception has been added to the principal amounts.
 
 
11

 
 
   The details of the convertible notes and loans are as follows at March 31, 2016:

                         
Fixed
 
                   
Conversion
   
Rate
 
Lender
1st-Issue
 
Principal
   
Duration
 
Interest
 
Price
   
EUR/USD
 
Price
Date
 
Amount
   
(Note)
 
Rate
 
(stated)
   
Conversion
 
                             
Eardley Holding A.G. (1)
06/23/2006
   E 167       (2 )
10% pa
  $ 0.10       N/A  
Anglo Irish Bank S.A.(3)
10/21/2007
   E 500       (2 )
10% pa
  $ 0.50       1.4090  
Round Enterprises Ltd.
12/10/2007
   E 1,500       (2 )
10% pa
  $ 0.50       1.4429  
Round Enterprises Ltd.
01/22/2008
   E 1,500       (2 )
10% pa
  $ 0.50       1.4629  
Round Enterprises Ltd.
04/25/2008
   E 2,000       (2 )
10% pa
  $ 0.50       1.5889  
Round Enterprises Ltd.
06/30/2008
   E 1,500       (2 )
10% pa
  $ 0.50       1.5380  
Round Enterprises Ltd.
11/18/2008
   E 1,200       (2 )
10% pa
  $ 0.50       1.2650  
Round Enterprises Ltd.
02/09/2009
   E 1,500       (2 )
10% pa
  $ 0.50       1.2940  
Round Enterprises Ltd.
06/15/2009
   E 5,500       (2,4 )
10% pa
  $ 0.80       1.4045  
Eardley Holding A.G.
06/15/2009
   E 100       (2,4 )
10% pa
  $ 0.80       1.4300  
Von Meyenburg
08/03/2009
   E 200       (2 )
10% pa
  $ 0.80       1.4400  
Round Enterprises Ltd.
10/13/2009
   E 2,000       (2 )
5% pa
  $ 0.25       1.4854  
Round Enterprises Ltd.
12/18/2009
   E 2,200       (2 )
5% pa
  $ 0.25       1.4338  
Round Enterprises Ltd.
08/04/2011
   E 1,057       (5,6 )
10% pa
  $ 0.034       N/A  
Eardley Holding A.G.
08/04/2011
   E 264       (5,6 )
10% pa
  $ 0.034       N/A  
Round Enterprises Ltd.
11/08/2011
   E 400       (6 )
10% pa
  $ 0.034       1.3787  
Eardley Holding A.G.
11/08/2011
   E 100       (6 )
10% pa
  $ 0.034       1.3787  
Round Enterprises Ltd.
02/10/2012
   E 1,000       (6 )
10% pa
  $ 0.034       1.3260  
Eardley Holding A.G.
02/14/2012
   E 200       (6 )
10% pa
  $ 0.034       1.3260  
Round Enterprises Ltd.
04/19/2012
   E 322       (6 )
10% pa
  $ 0.034       1.3100  
Eardley Holding A.G.
04/19/2012
   E 80       (6 )
10% pa
  $ 0.034       1.3100  
Round Enterprises Ltd.
05/04/2012
   E 480       (6 )
10% pa
  $ 0.034       1.3152  
Eardley Holding A.G.
05/04/2012
   E 120       (6 )
10% pa
  $ 0.034       1.3152  
Round Enterprises Ltd.
09/03/2012
   E 200       (6 )
10% pa
  $ 0.034       1.2576  
Eardley Holding A.G.
09/03/2012
   E 50       (6 )
10% pa
  $ 0.034       1.2576  
Round Enterprises Ltd.
11/14/2012
   E 500       (6 )
10% pa
  $ 0.034       1.2718  
Eardley Holding A.G.
12/06/2012
   E 125       (6 )
10% pa
  $ 0.034       1.3070  
Round Enterprises Ltd.
01/16/2013
   E 240       (6 )
10% pa
  $ 0.034       1.3318  
Eardley Holding A.G.
01/16/2013
   E 60       (6 )
10% pa
  $ 0.034       1.3318  
Round Enterprises Ltd.
03/25/2013
   E 400       (6 )
10% pa
  $ 0.037       1.2915  
Eardley Holding A.G.
04/14/2013
   E 150       (6 )
10% pa
  $ 0.034       1.3056  
Round Enterprises Ltd.
04/14/2013
   E 600       (6 )
10% pa
  $ 0.034       1.3056  
Eardley Holding A.G.
05/15/2013
   E 170       (6 )
10% pa
  $ 0.037       1.2938  
Round Enterprises Ltd.
05/15/2013
   E 680       (6 )
10% pa
  $ 0.037       1.2938  
Eardley Holding A.G.
06/24/2013
   E 60       (6 )
10% pa
  $ 0.025       1.3340  
Round Enterprises Ltd.
06/24/2013
   E 240       (6 )
10% pa
  $ 0.025       1.3340  
Eardley Holding A.G.
08/05/2013
   E 80       (6 )
10% pa
  $ 0.018       1.3283  
Round Enterprises Ltd.
08/05/2013
   E 320       (6 )
10% pa
  $ 0.018       1.3283  
Total Short Term Principal Amounts
     E 27,765                            
   Accrued Interest
     E 15,954                            
                                     
TOTAL LOANS AND NOTES
     E 43,719                            

(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

(2) This maturity date is automatically prolonged for periods of three months, unless called for repayment.

(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.

(5) The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively.
 
 
12

 

(6) This maturity date is automatically prolonged for periods of three months, unless called for repayment. The conversion price per share is determined by the lower of (i) reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than US$20,000, or (ii) at the stated conversion price using a fixed exchange rate which are noted in the table above.
 
Note 4. Subsequent Events

    On April 5, 2016, the Company announced that the preclinical study funded by PATH-MVI and in collaboration with LMIV where Mymetics’ virosome based formulations for a malaria transmission-blocking vaccine candidate were tested and compared with other vaccine formulations, had been successful. The study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite. The Company is currently evaluating funding opportunities for the next steps of development.
 
On April 11, 2016, the Company announced that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study. The blinded study was led by Dr. Ruth Ruprecht, Scientist & Director of the Texas Biomed AIDS Research Program and was funded by the Bill & Melinda Gates foundation. During the first part of the study the Mymetics’ two-component virosome-based HIV vaccine was able to show significant efficacy of 87% in delaying the time to persistent infection versus the control group after 7 intravaginal virus challenges.  The study aimed to mimic the exposure of women to semen from HIV-infected men, although the viral dose of each of these 7 animal challenges represented about 70,000 times the average human HIV dose passed during sexual intercourse from an HIV-infected male to an uninfected female.  During the second part of the study the animal viral challenge dose was increased by 50% starting from the 8th challenge onward, reaching more than 100,000 times the average amount of virus passed from an infected man to a female partner.  At this virus dose, the vaccine did not show significant protection in the animals as the immune system was overloaded. The Company is currently evaluating funding opportunities for the analysis of the mechanisms of action of the vaccine.
 
 
13

 
 
ITEM  2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL

The following discussion and analysis of the results of operations and financial condition of Mymetics Corporation for the periods ended March 31, 2016 and 2015 should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2015 and related notes and the description of the Company's business and properties included elsewhere herein.

This report contains forward-looking statements that involve risks and uncertainties. The statements contained in this report are not purely historical, but are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward looking statements concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Words such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue", "probably" or similar words are intended to identify forward looking statements, although not all forward looking statements contain these words.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We are under no duty to update any of the forward-looking statements after the date hereof to conform such statements to actual results or to changes in our expectations.

Readers are urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation disclosures made under the captions "Management Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Consolidated Financial Statements" and "Notes to Consolidated Financial Statements" included in our annual report on Form 10-K for the year ended December 31, 2015 and, to the extent included therein, our quarterly reports on Form 10-Q filed during fiscal year 2015.

THREE MONTHS ENDED MARCH 31, 2016 AND 2015

Revenue was E405 and E662 for the three months ended March 31, 2016 and 2015, respectively, mainly related to the research and development services provided under a License and Collaboration Agreement for the RSV vaccine signed on December 23, 2013 and revenue recognized for the work performed under the Horizon 2020 grants.

Costs and expenses decreased to E376 for the three months ended March 31, 2016 from E969 (-61.2%) for the three months ended March 31, 2015, mainly due to the reversal of aged R&D cost accrual of E154 during the three months ended March 31, 2016. For the 3 months period ending March 31, 2016, foreign exchange revaluation of existing US$ based loans from third party investors generated an unrealized gain of E92. For the 3 months period ending March 31, 2015, foreign exchange revaluation of existing US$ based loans from third party investors generated an unrealized loss of E234, while this was off-set against gains in US$ cash position, however still resulting in loss of E193.
 
Research and development expenses decreased to E109 in the current period from E367 (-70.3%) in the comparative period of 2015,  mainly due to the reversal of aged R&D cost accrual of E154 during the three months ended March 31, 2016.
 
General and administrative expenses decreased to E343 in the three months ended March 31, 2016 from E393 (-12.7%) in the comparative period of 2015.

Interest expense decreased to E642 for the three months ended March 31, 2016 from E643 for the three months ended March 31, 2015 related to existing loans from third party investors.

The Company reported a net loss of (E593), or (E0.00) per share, for the three months ended March 31, 2016, compared to a net loss of (E953), or (E0.00) per share, for the three months ended March 31, 2015.
 
LIQUIDITY AND CAPITAL RESOURCES

We had cash of E1,997 at March 31, 2016 compared to E2,381 at December 31, 2015.

 Our first significant revenue has been generated through the exclusive negotiation fee recorded in September 9, 2013 and the license and collaboration agreement for our RSV vaccine signed on December 27, 2013. As consideration Mymetics had received an irrevocable and non-refundable upfront fee for the license of USD 5 million at the beginning of 2014 and we have received fixed monthly collaboration and R&D fees. Due to the ending of the License and Collaboration Agreement with RSVC, for 2016, we anticipate to recognize small revenues related to the research and development activities related to the RSV vaccine and some revenues related to the Horizon 2020 project. New significant revenues will not be expected, unless and until a second major licensing agreement or other commercial arrangement is entered into with respect to our technology.
 
 
14

 

As of March 31, 2016, we had an accumulated deficit of approximately E71 million, and had net loss of E593 in the three month period ending on that date. We expect to continue to incur net losses in the future for research, development and activities related to the future licensing of our technologies, and because of the accrual of interest payable on existing loans.

Net cash used in operating activities was E378 for the three month period ended March 31, 2016 mainly due to the decrease in research and development revenue received from RSV Corporation. During the three month period ending March 31, 2015 net cash provided in operating activities was E39.

Investing activities was NIL during the three months ended March 31, 2016, compared to (E7) of cash used for the comparable period in 2015 related to the purchase of equipment for our laboratory in Leiden.

Financing activities for the three months ended March 31, 2016 and March 31, 2015 is NIL.

Salaries and related payroll costs represent gross salaries for two executives, our CSO of Mymetics BV and seven employees. Under Executive Employment Agreements with our CEO and two CSOs, we pay our executive officers a combined amount of E65 per month.

Our Swiss subsidiary, Mymetics S.A., has two employees on its payroll: Director of Finance and Head of Manufacturing and Quality. Mymetics BV has, besides the full time Chief Scientific Officer, four full-time technicians and one part-time assistant.

    We intend to continue to incur additional expenditures during the next nine months for additional research and development of our HIV and Malaria vaccines, which we will try to seek through collaborations with not-for-profit organizations. These expenditures will relate to the continued testing of its prototype vaccines and are included in the monthly cash outflow described above.

 In the past, we have financed our research and development activities primarily through debt and equity financings from various parties, while the last two years our financing was generated through a license and collaboration agreement and grant agreements
 
We anticipate that our normal operations will require approximately E1,650 in the year ending December 31, 2016. We will seek to raise the required capital from equity or debt financings, and grants through donors and potential partnerships with major international pharmaceutical and biotechnology firms. However, there can be no assurance that we will be able to raise additional capital on satisfactory terms, or at all, to finance our operations. In the event that we are not able to obtain such additional capital, we will be required to further restrict or even cease our operations.
 
Monthly fixed and recurring expenses for "Property leases" of E14 represent the monthly lease and maintenance payments to unaffiliated third parties for our offices, of which E4 is related to our executive office located at Route de la Corniche 4, 1066 Epalinges in Switzerland (100 square meters), and E10 related to Bestewil Holding B.V. and its subsidiary Mymetics B.V operating from a similar biotechnology campus near Leiden in the Netherlands, where they occupy 150 square meters.
 
Included in professional fees are legal fees paid to outside corporate counsel and audit and review fees paid to our independent accountants, and fees paid for investor relations.
 
Cumulative interest expense of E15,954 has been accrued on all of the Company’s outstanding notes and advances (see detailed table in Note 3 to the financial statements).

RECENT FINANCING ACTIVITIES

 During the three month period ending March 31, 2016, our principal source of funds has been revenues related to a License and Collaboration Agreement (“LCA”) with RSV Corporation (“RSVC”) signed on December 27, 2013 to license Bestewil Holding BV.
 
We have filed or are in the process of filing several new grant applications with U.S. and European institutions in relation to our HIV and malaria vaccines.
 
We anticipate using our current funds and those we receive in the future both to meet our working capital needs and for funding the ongoing vaccines pre-clinical research costs for new virosome vaccine.
 
Management anticipates that our existing capital resources will be sufficient to fund our cash requirements through the next nine months. We have enough cash presently on hand in conjunction with the collection of receivables, based upon our current levels of expenditures and anticipated needs during this period. For 2017, we will need additional funding through future collaborative arrangements, licensing arrangements, and debt and equity financings under Regulation D and Regulation S under the Securities Act of 1933. We do not know whether additional financing will be available on commercially acceptable terms when needed.
 
 
15

 
 
If management cannot raise funds on acceptable terms when needed, we may not be able to successfully commercialize our technologies, take advantage of future opportunities, or respond to unanticipated requirements. If unable to secure such additional financing when needed, we will have to curtail or suspend all or a portion of our business activities and could be required to cease operations entirely. Further, if new equity securities are issued, our shareholders may experience severe dilution of their ownership percentage.
 
The extent and timing of our future capital requirements will depend primarily upon the rate of our progress in the research and development of our technologies, our ability to enter into a partnership agreement with a major pharmaceutical company, and the results of our present and future clinical trials.

OFF-BALANCE SHEET ARRANGEMENTS

None
 
 
16

 
 
ITEM 3.                      QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk from changes in interest rates which could affect our financial condition and results of operations. We have not entered into derivative contracts for our own account to hedge against such risk.

INTEREST RATE RISK

Fluctuations in interest rates may affect the fair value of financial instruments. An increase in market interest rates may increase interest payments and a decrease in market interest rates may decrease interest payments of such financial instruments. We have no debt obligations which are sensitive to interest rate fluctuations as all our notes payable have fixed interest rates, as specified on the individual loan notes.
 
ITEM 4.
CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, as appropriate, to allow timely decisions regarding required disclosure. Our management, with the participation and supervision of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and determined that our disclosure controls and procedures were effective.
 
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

No changes of internal control over financial reporting were made in the three months ended March 31, 2016.

INHERENT LIMITATIONS ON EFFECTIVENESS OF CONTROLS

Our management, Ronald Kempers, who is now both CEO and CFO, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected.

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.
 
 
17

 
 
PART II. 
OTHER INFORMATION

ITEM 1.
LEGAL PROCEEDINGS

Neither we, nor our wholly owned subsidiaries Mymetics S.A., Bestewil Holding B.V. nor its subsidiary Mymetics B.V. are presently involved in any litigation incident to our business.

ITEM 1A.
RISK FACTORS

Not applicable.

ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3.
DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.
MINE SAFETY DISCLOSURES

None.

ITEM 5.
OTHER INFORMATION

None.

ITEM 6.
EXHIBITS
 
 
EXHIBIT NUMBER
DESCRIPTION
 
Rule 13a-14(a)/15d-14(a) Certification of Chief
 
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
 
Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
                 
101.INS
Instance Document

101.SCH
XBRL Taxonomy Extension Schema Document

101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
 
101.LAB
XBRL Taxonomy Extension Label Linkbase Document

101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
18

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
MYMETICS CORPORATION
 
       
Dated:  May 12, 2016
By: 
/s/ Ronald Kempers
 
   
Chief Executive Officer / Chief Financial Officer
 
       
 
 
 
 
 
EX-31.1 2 ex_311.htm CERTIFICATION ex_311.htm
Exhibit 31.1
 
 

CHIEF EXECUTIVE OFFICER I, Ronald Kempers, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Mymetics Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

     (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

     (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

     (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

     (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

     (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

     (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
     
       
Date: May 12, 2016
By:
/s/  Ronald Kempers  
     Ronald Kempers  
     Chief Executive Officer  
       

 




 
EX-31.2 3 ex_312.htm CERTIFICATION ex_312.htm
                                                                             Exhibit 31.2

CHIEF FINANCIAL OFFICER I, Ronald Kempers, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Mymetics Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

     (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

     (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

      (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

     (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

     (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

     (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
     
       
Date: May 12, 2016
By:
/s/  Ronald Kempers  
     Ronald Kempers  
    Chief Financial Officer  
       

 
 
EX-32 4 ex_32.htm CERTIFICATION ex_32.htm
                                                                           Exhibit 32


PURSUANT TO 18 U.S.C. 1350


Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of Mymetics Corporation, a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

The Quarterly Report on Form 10-Q for the three months ended March 31, 2016 (the "Form 10-Q") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
     
       
Dated: May 12, 2016
By:
/s/  Ronald Kempers  
     Ronald Kempers  
     Chief Executive Officer / Chief Financial Officer  
       
 
The foregoing certification is being furnished solely pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as a separate disclosure document.

EX-101.INS 5 mymx-20160331.xml 0000927761 2016-01-01 2016-03-31 0000927761 2015-12-31 0000927761 2016-03-31 0000927761 2015-01-01 2015-03-31 0000927761 2015-03-31 0000927761 us-gaap:ConvertibleDebtSecuritiesMember 2016-01-01 2016-03-31 0000927761 us-gaap:ConvertibleDebtSecuritiesMember 2015-01-01 2015-03-31 0000927761 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000927761 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-03-31 0000927761 2016-05-12 0000927761 2014-12-31 xbrli:shares iso4217:EUR iso4217:USD xbrli:shares iso4217:EUR xbrli:shares MYMETICS CORP 0000927761 --12-31 No No Yes Smaller Reporting Company 2016 Q1 10-Q false 2016-03-31 .01 .01 1000000000 1000000000 .01 .01 5000000 5000000 MYMX 303757622 2665000 2196000 66000 87000 218000 112000 2381000 1997000 1709000 1614000 106000 96000 11708000 11229000 6671000 6671000 2266000 2266000 44600000 44692000 43170000 43719000 1014000 828000 416000 145000 2530000 2530000 0 0 11708000 11229000 -32892000 -33463000 690000 684000 -70427000 -71020000 34315000 34343000 314000 324000 303757622 303757622 0 0 0 0 405000 662000 186000 52000 219000 610000 29000 -307000 376000 969000 92000 -193000 5000 5000 10000 10000 1000 1000 343000 393000 109000 367000 -613000 -950000 642000 643000 -593000 -953000 -20000 3000 -6000 63000 -599000 -890000 0.00 0.00 0.00 0.00 28000 15000 -378000 39000 -21000 -1000 -186000 0 -271000 112000 549000 877000 -106000 21000 0 7000 0 -7000 0 0 -6000 63000 -384000 95000 <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>BASIS OF PRESENTATION</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The amounts in the notes are shown in thousands of EURO rounded to the nearest thousand except for share and per share amounts.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The accompanying interim period consolidated financial statements of Mymetics Corporation (the &#34;Company&#34;) set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the &#34;SEC&#34;). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2015.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three-month period ending March 31, 2016 were of a normal and recurring nature.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">Mymetics Corporation (the &#34;Company&#34; or &#34;Mymetics&#34;) was created for the purpose of engaging in vaccine research and development. Its main research efforts in the beginning have been concentrated in the prevention and treatment of the AIDS virus and malaria and has later expanded to other vaccines for infectious diseases since the acquisition of Bestewil Holding BV in April 2009. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. The Company has the following vaccines under development; (i) Herpes Simplex which is at the pre-clinical stage and currently on hold, (ii) intranasal influenza which has finished a clinical trial Phase I for which the Company is seeking partners (iii) Respiratory Syncytial Virus (RSV) which is at the pre-clinical stage, (iv) HIV-1 which has finished a Phase I and is currently in a repeat non-human primate study with the Texas Biomedical Research Institute, (v) malaria, which has finished a Phase Ib and a malaria transmission blocking vaccine which is in pre-clinical study with PATH-MVI and LMIV and (vi) two vaccine candidates that are currently in a discovery phase, one for Chikungunya and one for Zika.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">As of March 31, 2016, the Company is in the pre-clinical testing of some of its vaccine candidates and a commercially viable product is not expected for several more years. However, the Company generates some revenue through the licensing of its RSV vaccine and from collaboration and grant agreements for R&#38;D services. Management believes that the Company&#146;s research and development activities will result in valuable intellectual property that can generate significant revenues in the future such as by licensing. Vaccines are one of the fastest growing markets in the pharmaceutical industry.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">These consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced significant losses since inception resulting in an accumulated deficit of E71,020 at March 31, 2016. Further, the Company&#146;s current liabilities exceed its current assets by E42,496 as of March 31, 2016, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts. These conditions raise substantial doubt about our ability to continue as a going concern.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>PRINCIPLES OF CONSOLIDATION</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>FOREIGN CURRENCY TRANSLATION</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>CASH</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">Cash deposits are occasionally in excess of insured amounts.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>REVENUE RECOGNITION</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Exclusive Licenses</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The deliverables under an exclusive license agreement generally include the exclusive license to the Company&#146;s technology, and may also include deliverables related to research activities to be performed on behalf of the collaborative collaborator and the manufacture of preclinical or clinical materials for the collaborative collaborator.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">Generally, exclusive license agreements contain non-refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) provide research services which are reimbursed at a contractually determined rate which includes margin for the Company, (ii) participate in a joint steering committee to monitor the progress of the research and development which will be reimbursed at a contractually determined rate which includes margin for the Company, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments at the time of commercialization until the later of expiration of the last to expire valid patent rights expire or 10 years after the first commercial sale. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements.&#160;&#160;The Company does not directly control when any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments.&#160;&#160;As a result, the Company cannot predict when it will recognize revenues in connection with any of the foregoing.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, &#34;Revenue Recognition&#151;Multiple-Element Arrangements,&#34; and ASC Topic 605-28, &#34;Revenue Recognition&#151;Milestone Method,&#34; in accounting for these agreements.&#160;&#160;In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the collaborator.&#160;&#160;The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Factors considered in this determination include the research and manufacturing capabilities of the collaborator and the availability of technology research expertise in the general marketplace</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>RSV Corporation</u></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">In December 2013, the Company entered into an agreement with RSV Corporation. The agreement provided RSV Corporation with an exclusive license to the Company&#146;s RSV technology in order to develop and commercialize respiratory syncytial virus virosome vaccines. The Company received a US$5 million upfront payment in connection with the execution of the agreement and the Company was entitled to receive milestone payments potentially totaling $77 million plus royalties on product sales, if any. The Company also was entitled to receive payments for research and development activities performed on behalf of RSV Corporation. RSV Corporation was responsible for the development, manufacturing, and marketing of any products resulting from this agreement.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the agreement. The significant deliverables were determined to be the RSV technology license and the research and development services including participation on the Joint Collaboration and Steering Committee (JCSC). The Company determined that the RSV technology license had standalone value from the research services. As a result, the research services were considered a separate unit of accounting. The estimated selling prices for these units of accounting were determined based on market conditions and entity-specific factors such as the terms of the collaborators&#146; previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company&#146;s RSV technology, the Company&#146;s pricing practices and pricing objectives, and the nature of the research services to be performed for RSV Corporation and market rates for similar services. The arrangement consideration was allocated to the deliverables based on the relative selling price method. The Company recognized license revenue when the exclusive license was delivered pursuant to the terms of the agreement which was upon execution of the agreement. The Company recognized research services revenue as the related services were delivered.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;On January 25, 2016 Mymetics received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious therapies. The LCA which was signed on December 27, 2013, between Bestewil Holding BV and RSVC will formally be terminated as of July 25, 2016.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Fixed price contracts and research and collaboration agreements</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">When the performance under a fixed price contract can be reasonably estimated, revenue for such a contract is recognized under the proportional performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses. If the performance under a fixed price contract cannot be reasonably estimated, the Company recognizes the revenue on a straight-line basis over the contract term.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>TEXAS BIOMEDICAL RESEARCH INSTITUTE</u></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;In September 2014, the Company entered into a material transfer agreement and fixed price contract with Texas Biomedical Research Institute. The agreement provides Texas Biomedical Research Institute the lead of a project which has been proposed to the Bill and Melinda Gates foundation with the objective to confirm previous results obtained in non-human primates with these virosome based HIV vaccine candidates. The Company has tested these different formulations of virosome based HIV vaccines candidates in preclinical non-human primate studies and in Phase I clinical settings. The Company produced and transferred to Texas Biomedical Research Institute the original material using the Company&#146;s background IP. Results of the project with Texas Biomedical Research Institute was received in April 2016 (see note on subsequent events). The Company recognizes revenue under the proportional performance method.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>PATH-MVI</u></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">In November 2014, the Company signed an agreement with PATH Malaria Vaccine Initiative (MVI) and the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), where Mymetics has developed and produced virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate which are based on two antigens provided by LMIV. The vaccine formulations were then tested in animal models. PATH MVI funded all activities under this project, which started in January 2015 and ended in January 2016. The Company has recognized revenue under the proportional performance method.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>HORIZON 2020</u></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">In April 2015, the Company was selected to receive project grants with a total of E8.4 million. A total of E5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program and up to E3.1 million of funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The grant funds the evaluation, development and manufacturing scale-up of thermo-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Of the total amount, E3.4 million is directly attributable to Mymetics activities, with the remaining balance going to the consortium partners. The project duration is 42 months and started on May 4, 2015. In May 2015, the Company received a pre-payment from the two granting organizations for a total value of E1.5 million. The pre-payment has been recorded as a current liability and revenue has been recognized as services are delivered.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>RECEIVABLES</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. There was no allowance necessary at March 31, 2016 or December 31, 2015. The Company charges off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>PROPERTY AND EQUIPMENT</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>IN-PROCESS RESEARCH AND DEVELOPMENT</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">In-process research and development (referred to as IPR&#38;D) represents the estimated fair value assigned to research and development projects acquired in a purchased business combination that have not been completed at the date of acquisition and which have no alternative future use. IPR&#38;D assets acquired in a business combination are capitalized as indefinite-lived intangible assets. These assets remain indefinite-lived until the completion or abandonment of the associated research and development efforts. During the periods prior to completion or abandonment, those acquired indefinite-lived assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">IMPAIRMENT OF LONG LIVED ASSETS</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">Long-lived assets, which include property and equipment, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset&#146;s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income in the period that the impairment occurs.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>GOODWILL</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis as of April 1 of each year, unless events or circumstances indicate impairment may have occurred before that time. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. After assessing qualitative factors, the Company must determine if further testing was necessary. If further testing was necessary, the Company would have performed a two-step impairment test for goodwill. The first step requires the Company to determine the fair value of each reporting unit. To the extent a reporting unit&#146;s carrying amount exceeds its fair value, an indication exists that the reporting unit&#146;s goodwill may be impaired and the Company must perform a second more detailed impairment assessment. The second impairment assessment involves allocating the reporting unit&#146;s fair value to all of its recognized and unrecognized assets and liabilities in order to determine the implied fair value of the reporting unit&#146;s goodwill as of the assessment date. The implied fair value of the reporting unit&#146;s goodwill is then compared to the carrying amount of goodwill to quantify an impairment charge as of the assessment date.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The Company has conducted its impairment testing as of April 1, of 2016 and 2015 of its goodwill recognized in connection to the acquisition of Bestewil. In conclusion of this impairment testing, the carrying amount of the reporting unit was lower than the estimated fair value of the reporting unit. As the fair value of the reporting unit is higher than the carrying amount, Step 2 of the goodwill impairment test did not need to be completed. As of March 31, 2016, management believes there are no indications of impairment.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>RESEARCH AND DEVELOPMENT</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">Research and development costs are expensed as incurred.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif"><i>&#160;</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>TAXES ON INCOME</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The Company reports a liability, if any, for unrecognized tax benefits resulting from uncertain income tax positions taken or expected to be taken in an income tax return. Estimated interest and penalties, if any, are recorded as a component of interest expense and other expense, respectively.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The Company has not recorded any liabilities for uncertain tax positions or any related interest and penalties at March 31, 2016 or December 31, 2015. The Company&#146;s United States tax returns are open to audit for the years ended December 31, 2012 to 2015. The returns for the Swiss subsidiary, Mymetics S.A., are open to audit for the years ended December 31, 2010 to 2015. The returns for the Netherlands subsidiaries, Bestewil B.V. and Mymetics B.V., are open to audit for the year ended December 31, 2015.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>EARNINGS PER SHARE</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Basic earnings per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. For the quarters ended March 31, 2016 and 2015, options and convertible debt were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred under the treasury stock method.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">For the three months ended March 31, 2016, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 559,614,329 at March 31, 2016 includes 530,034,329 potential issuable shares related to convertible loans and 29,580,000 potential issuable shares related to outstanding not expired options granted to employees.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160; For the three months ended March 31, 2015, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 494,877,358 at March 31, 2015 includes 474,027,358 potential issuable shares related to convertible loans, and 20,850,000 potential issuable shares related to outstanding stock options granted to employees.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>PREFERRED STOCK</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying dividend, conversion and voting rights. No preferred shares are issued or outstanding at March 31, 2016 or December 31, 2015.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>STOCK-BASED COMPENSATION</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Compensation cost for all share-based payments is based on the estimated grant-date fair value. The Company amortizes stock compensation cost ratably over the requisite service period.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The issuance of common shares for services is recorded at the quoted price of the shares on the date the shares are issued. No shares were issued to individuals as fee for services rendered in the three months ended March 31, 2016 nor in the three months ended March 31, 2015.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">Stock compensation expense amounted to E28 and E15 during the three months periods ended March 31, 2016 and 2015, respectively, and is included in the statement of operations within general and administrative expenses.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>ESTIMATES</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>FAIR VALUE MEASUREMENTS</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="width: 7%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Level 1- </font></td> <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="width: 92%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Quoted prices in active markets for identical assets or liabilities.</font></td></tr> <tr style="font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Level 2- </font></td> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities</font></td></tr> <tr style="background-color: #CCEEFF; font: 8pt Times New Roman, Times, Serif"> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;Level 3- </font></td> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>FAIR VALUES OF FINANCIAL INSTRUMENTS</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The Company generally has the following financial instruments: cash, receivables, accounts payable, and notes payable. The carrying value of cash, receivables and accounts payable, approximates their fair value based on the short-term nature of these financial instruments. Management believes that it is not practicable to estimate the fair value of the notes payable due to the unique nature of these instruments.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>CONCENTRATIONS</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;&#160; The Company derived 54% and 94% of revenue from its relationship with one collaborative partner during the three month periods ended March 31, 2016 and March 31, 2015, respectively. Furthermore, that same collaborative partner accounted for 68% of the receivables balance at December 31, 2015 and 38% of the receivables balance at March 31, 2016.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>RELATED PARTY TRANSACTIONS</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">An individual employed by the law firm that acts as the Company's general counsel is a member of the Board of Directors.&#160; The Company incurred professional fees to the counsel's law firm totaling E5 and E7 for the period of three months ended March 31, 2016 and 2015, respectively.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>NEW ACCOUNTING PRONOUNCEMENTS</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160; &#160; In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the fiscal and interim reporting periods beginning after December 15, 2017 using either of two methods:</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 48px; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(i)&#160;&#160;</font></td> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font: 8pt Times New Roman, Times, Serif"> <td style="width: 48px; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(ii)&#160;&#160;</font></td> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09.</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;Management is currently evaluating the impact of the Company's pending adoption of ASU 2014-09 on its consolidated financial statements.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Intangible assets consisted of in process research and development at March 31, 2016 and December 31, 2015.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Certain principal shareholders have granted the Company secured convertible notes (in accordance with the Uniform Commercial Code in the State of Delaware) and short term convertible notes, which have a total carrying value of E43,719 including interest due to date. Interest incurred on these notes since inception has been added to the principal amounts.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;&#160;&#160;The details of the convertible notes and loans are as follows at March 31, 2016:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Fixed</b></font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Conversion</b></font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Rate</b></font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt"><b>Lender</b></font></td> <td style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>1st-Issue</b></font></td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Principal</b></font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Duration</b></font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Interest</b></font></td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Price</b></font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>EUR/USD</b></font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt"><b>Price</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Date</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Amount</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>(Note)</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Rate</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>(stated)</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Conversion</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 27%; text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G. (1)</font></td> <td style="width: 13%; text-indent: -9pt"><font style="font-size: 8pt">06/23/2006</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">&#160;E</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">167</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap" style="width: 1%"><font style="font-size: 8pt">)</font></td> <td style="width: 12%; text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">0.10</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">N/A</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Anglo Irish Bank S.A.(3)</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">10/21/2007</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4090</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">12/10/2007</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4429</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">01/22/2008</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4629</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/25/2008</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">2,000</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.5889</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/30/2008</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.5380</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">11/18/2008</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2650</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">02/09/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2940</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/15/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">5,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2,4 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4045</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/15/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">100</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2,4 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4300</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Von Meyenburg</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">08/03/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4400</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">10/13/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">2,000</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">5% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.25</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4854</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">12/18/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">2,200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">5% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.25</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4338</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">08/04/2011</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,057</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(5,6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">08/04/2011</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">264</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(5,6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">11/08/2011</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">400</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3787</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">11/08/2011</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">100</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3787</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">02/10/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,000</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3260</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">02/14/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3260</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/19/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">322</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3100</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/19/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3100</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">05/04/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">480</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3152</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">05/04/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">120</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3152</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">09/03/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2576</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">09/03/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2576</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">11/14/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2718</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">12/06/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">125</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3070</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">01/16/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">240</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3318</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">01/16/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">60</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3318</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">03/25/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">400</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.037</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2915</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/14/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">150</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3056</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/14/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">600</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3056</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">05/15/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">170</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.037</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2938</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">05/15/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">680</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.037</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2938</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/24/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">60</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.025</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3340</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/24/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">240</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.025</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3340</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">08/05/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.018</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3283</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="padding-bottom: 1.5pt; text-indent: -9pt"><font style="font-size: 8pt">08/05/2013</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 8pt">&#160;E</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">320</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td> <td style="padding-bottom: 1.5pt; text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">$</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">0.018</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">1.3283</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Total Short Term Principal Amounts</font></td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">27,765</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;&#160;&#160;Accrued Interest</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 8pt">&#160;E</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">15,954</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt; text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">TOTAL LOANS AND NOTES</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;E</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">43,719</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(2) This maturity date is automatically prolonged for periods of three months, unless called for repayment.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(5) The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(6) This maturity date is automatically prolonged for periods of three months, unless called for repayment. The conversion price per share is determined by the lower of (i) reducing by 10% the price per share of the Company&#146;s common stock paid by the investors in connection with an investment in the Company of not less than US$20,000, or (ii) at the stated conversion price using a fixed exchange rate which are noted in the table above.</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: bottom"><td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Fixed</b></font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Conversion</b></font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Rate</b></font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt"><b>Lender</b></font></td> <td style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>1st-Issue</b></font></td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Principal</b></font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Duration</b></font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Interest</b></font></td> <td>&#160;</td> <td colspan="2" style="text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Price</b></font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>EUR/USD</b></font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt"><b>Price</b></font></td> <td style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Date</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Amount</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>(Note)</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>Rate</b></font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; text-indent: -9pt"><font style="font-size: 8pt"><b>(stated)</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 8pt"><b>Conversion</b></font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 27%; text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G. (1)</font></td> <td style="width: 13%; text-indent: -9pt"><font style="font-size: 8pt">06/23/2006</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">&#160;E</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">167</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap" style="width: 1%"><font style="font-size: 8pt">)</font></td> <td style="width: 12%; text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%"><font style="font-size: 8pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">0.10</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%; text-align: right">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><font style="font-size: 8pt">N/A</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Anglo Irish Bank S.A.(3)</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">10/21/2007</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4090</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">12/10/2007</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4429</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">01/22/2008</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4629</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/25/2008</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">2,000</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.5889</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/30/2008</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.5380</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">11/18/2008</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2650</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">02/09/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2940</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/15/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">5,500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2,4 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4045</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/15/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">100</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2,4 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4300</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Von Meyenburg</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">08/03/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4400</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">10/13/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">2,000</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">5% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.25</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4854</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">12/18/2009</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">2,200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(2 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">5% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.25</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.4338</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">08/04/2011</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,057</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(5,6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">08/04/2011</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">264</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(5,6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">11/08/2011</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">400</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3787</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">11/08/2011</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">100</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3787</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">02/10/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">1,000</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3260</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">02/14/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3260</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/19/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">322</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3100</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/19/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3100</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">05/04/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">480</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3152</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">05/04/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">120</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3152</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">09/03/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">200</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2576</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">09/03/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">50</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2576</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">11/14/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">500</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2718</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">12/06/2012</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">125</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3070</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">01/16/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">240</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3318</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">01/16/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">60</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3318</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">03/25/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">400</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.037</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2915</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/14/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">150</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3056</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">04/14/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">600</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.034</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3056</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">05/15/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">170</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.037</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2938</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">05/15/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">680</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.037</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.2938</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/24/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">60</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.025</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3340</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">06/24/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">240</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.025</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3340</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Eardley Holding A.G.</font></td> <td style="text-indent: -9pt"><font style="font-size: 8pt">08/05/2013</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">80</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap"><font style="font-size: 8pt">)</font></td> <td style="text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">$</font></td> <td style="text-align: right"><font style="font-size: 8pt">0.018</font></td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">1.3283</font></td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">Round Enterprises Ltd.</font></td> <td style="padding-bottom: 1.5pt; text-indent: -9pt"><font style="font-size: 8pt">08/05/2013</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 8pt">&#160;E</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">320</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">(6 </font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td> <td style="padding-bottom: 1.5pt; text-align: right; text-indent: -9pt"><font style="font-size: 8pt">10% pa</font></td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">$</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">0.018</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 8pt">1.3283</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">Total Short Term Principal Amounts</font></td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td><font style="font-size: 8pt">&#160;E</font></td> <td style="text-align: right"><font style="font-size: 8pt">27,765</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">&#160;&#160;&#160;Accrued Interest</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 8pt">&#160;E</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 8pt">15,954</font></td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 3pt; text-indent: -9pt; padding-left: 10pt"><font style="font-size: 8pt">TOTAL LOANS AND NOTES</font></td> <td style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 8pt">&#160;E</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 8pt">43,719</font></td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td>&#160;</td> <td style="padding-bottom: 3pt; text-align: right">&#160;</td> <td nowrap="nowrap" style="padding-bottom: 3pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(2) This maturity date is automatically prolonged for periods of three months, unless called for repayment.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(5) The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">(6) This maturity date is automatically prolonged for periods of three months, unless called for repayment. The conversion price per share is determined by the lower of (i) reducing by 10% the price per share of the Company&#146;s common stock paid by the investors in connection with an investment in the Company of not less than US$20,000, or (ii) at the stated conversion price using a fixed exchange rate which are noted in the table above.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The amounts in the notes are shown in thousands of EURO rounded to the nearest thousand except for share and per share amounts.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The accompanying interim period consolidated financial statements of Mymetics Corporation (the &#34;Company&#34;) set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the &#34;SEC&#34;). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2015.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three-month period ending March 31, 2016 were of a normal and recurring nature.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Mymetics Corporation (the &#34;Company&#34; or &#34;Mymetics&#34;) was created for the purpose of engaging in vaccine research and development. Its main research efforts in the beginning have been concentrated in the prevention and treatment of the AIDS virus and malaria and has later expanded to other vaccines for infectious diseases since the acquisition of Bestewil Holding BV in April 2009. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. The Company has the following vaccines under development; (i) Herpes Simplex which is at the pre-clinical stage and currently on hold, (ii) intranasal influenza which has finished a clinical trial Phase I for which the Company is seeking partners (iii) Respiratory Syncytial Virus (RSV) which is at the pre-clinical stage, (iv) HIV-1 which has finished a Phase I and is currently in a repeat non-human primate study with the Texas Biomedical Research Institute, (v) malaria, which has finished a Phase Ib and a malaria transmission blocking vaccine which is in pre-clinical study with PATH-MVI and LMIV and (vi) two vaccine candidates that are currently in a discovery phase, one for Chikungunya and one for Zika.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">As of March 31, 2016, the Company is in the pre-clinical testing of some of its vaccine candidates and a commercially viable product is not expected for several more years. However, the Company generates some revenue through the licensing of its RSV vaccine and from collaboration and grant agreements for R&#38;D services. Management believes that the Company&#146;s research and development activities will result in valuable intellectual property that can generate significant revenues in the future such as by licensing. Vaccines are one of the fastest growing markets in the pharmaceutical industry.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">These consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced significant losses since inception resulting in an accumulated deficit of E71,020 at March 31, 2016. Further, the Company&#146;s current liabilities exceed its current assets by E42,496 as of March 31, 2016, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts. These conditions raise substantial doubt about our ability to continue as a going concern.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Cash deposits are occasionally in excess of insured amounts.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0pt"><font style="font: 8pt Times New Roman, Times, Serif"><i>Exclusive Licenses</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The deliverables under an exclusive license agreement generally include the exclusive license to the Company&#146;s technology, and may also include deliverables related to research activities to be performed on behalf of the collaborative collaborator and the manufacture of preclinical or clinical materials for the collaborative collaborator.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">Generally, exclusive license agreements contain non-refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) provide research services which are reimbursed at a contractually determined rate which includes margin for the Company, (ii) participate in a joint steering committee to monitor the progress of the research and development which will be reimbursed at a contractually determined rate which includes margin for the Company, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments at the time of commercialization until the later of expiration of the last to expire valid patent rights expire or 10 years after the first commercial sale. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements.&#160;&#160;The Company does not directly control when any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments.&#160;&#160;As a result, the Company cannot predict when it will recognize revenues in connection with any of the foregoing.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">The Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, &#34;Revenue Recognition&#151;Multiple-Element Arrangements,&#34; and ASC Topic 605-28, &#34;Revenue Recognition&#151;Milestone Method,&#34; in accounting for these agreements.&#160;&#160;In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the collaborator.&#160;&#160;The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Factors considered in this determination include the research and manufacturing capabilities of the collaborator and the availability of technology research expertise in the general marketplace</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>RSV Corporation</u></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">In December 2013, the Company entered into an agreement with RSV Corporation. The agreement provided RSV Corporation with an exclusive license to the Company&#146;s RSV technology in order to develop and commercialize respiratory syncytial virus virosome vaccines. The Company received a US$5 million upfront payment in connection with the execution of the agreement and the Company was entitled to receive milestone payments potentially totaling $77 million plus royalties on product sales, if any. The Company also was entitled to receive payments for research and development activities performed on behalf of RSV Corporation. RSV Corporation was responsible for the development, manufacturing, and marketing of any products resulting from this agreement.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the agreement. The significant deliverables were determined to be the RSV technology license and the research and development services including participation on the Joint Collaboration and Steering Committee (JCSC). The Company determined that the RSV technology license had standalone value from the research services. As a result, the research services were considered a separate unit of accounting. The estimated selling prices for these units of accounting were determined based on market conditions and entity-specific factors such as the terms of the collaborators&#146; previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company&#146;s RSV technology, the Company&#146;s pricing practices and pricing objectives, and the nature of the research services to be performed for RSV Corporation and market rates for similar services. The arrangement consideration was allocated to the deliverables based on the relative selling price method. The Company recognized license revenue when the exclusive license was delivered pursuant to the terms of the agreement which was upon execution of the agreement. The Company recognized research services revenue as the related services were delivered.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt"><font style="font: 8pt Times New Roman, Times, Serif">&#160;&#160;On January 25, 2016 Mymetics received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious therapies. The LCA which was signed on December 27, 2013, between Bestewil Holding BV and RSVC will formally be terminated as of July 25, 2016.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><i>Fixed price contracts and research and collaboration agreements</i></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">When the performance under a fixed price contract can be reasonably estimated, revenue for such a contract is recognized under the proportional performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses. If the performance under a fixed price contract cannot be reasonably estimated, the Company recognizes the revenue on a straight-line basis over the contract term.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>TEXAS BIOMEDICAL RESEARCH INSTITUTE</u></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;In September 2014, the Company entered into a material transfer agreement and fixed price contract with Texas Biomedical Research Institute. The agreement provides Texas Biomedical Research Institute the lead of a project which has been proposed to the Bill and Melinda Gates foundation with the objective to confirm previous results obtained in non-human primates with these virosome based HIV vaccine candidates. The Company has tested these different formulations of virosome based HIV vaccines candidates in preclinical non-human primate studies and in Phase I clinical settings. The Company produced and transferred to Texas Biomedical Research Institute the original material using the Company&#146;s background IP. Results of the project with Texas Biomedical Research Institute was received in April 2016 (see note on subsequent events). The Company recognizes revenue under the proportional performance method.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>PATH-MVI</u></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">In November 2014, the Company signed an agreement with PATH Malaria Vaccine Initiative (MVI) and the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), where Mymetics has developed and produced virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate which are based on two antigens provided by LMIV. The vaccine formulations were then tested in animal models. PATH MVI funded all activities under this project, which started in January 2015 and ended in January 2016. The Company has recognized revenue under the proportional performance method.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif"><u>HORIZON 2020</u></font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in"><font style="font: 8pt Times New Roman, Times, Serif">In April 2015, the Company was selected to receive project grants with a total of E8.4 million. A total of E5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program and up to E3.1 million of funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The grant funds the evaluation, development and manufacturing scale-up of thermo-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Of the total amount, E3.4 million is directly attributable to Mymetics activities, with the remaining balance going to the consortium partners. The project duration is 42 months and started on May 4, 2015. In May 2015, the Company received a pre-payment from the two granting organizations for a total value of E1.5 million. The pre-payment has been recorded as a current liability and revenue has been recognized as services are delivered.</font></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. There was no allowance necessary at March 31, 2016 or December 31, 2015. The Company charges off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">In-process research and development (referred to as IPR&#38;D) represents the estimated fair value assigned to research and development projects acquired in a purchased business combination that have not been completed at the date of acquisition and which have no alternative future use. IPR&#38;D assets acquired in a business combination are capitalized as indefinite-lived intangible assets. These assets remain indefinite-lived until the completion or abandonment of the associated research and development efforts. During the periods prior to completion or abandonment, those acquired indefinite-lived assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Long-lived assets, which include property and equipment, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset&#146;s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income in the period that the impairment occurs.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis as of April 1 of each year, unless events or circumstances indicate impairment may have occurred before that time. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. After assessing qualitative factors, the Company must determine if further testing was necessary. If further testing was necessary, the Company would have performed a two-step impairment test for goodwill. The first step requires the Company to determine the fair value of each reporting unit. To the extent a reporting unit&#146;s carrying amount exceeds its fair value, an indication exists that the reporting unit&#146;s goodwill may be impaired and the Company must perform a second more detailed impairment assessment. The second impairment assessment involves allocating the reporting unit&#146;s fair value to all of its recognized and unrecognized assets and liabilities in order to determine the implied fair value of the reporting unit&#146;s goodwill as of the assessment date. The implied fair value of the reporting unit&#146;s goodwill is then compared to the carrying amount of goodwill to quantify an impairment charge as of the assessment date.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company has conducted its impairment testing as of April 1, of 2016 and 2015 of its goodwill recognized in connection to the acquisition of Bestewil. In conclusion of this impairment testing, the carrying amount of the reporting unit was lower than the estimated fair value of the reporting unit. As the fair value of the reporting unit is higher than the carrying amount, Step 2 of the goodwill impairment test did not need to be completed. As of March 31, 2016, management believes there are no indications of impairment.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Research and development costs are expensed as incurred.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company reports a liability, if any, for unrecognized tax benefits resulting from uncertain income tax positions taken or expected to be taken in an income tax return. Estimated interest and penalties, if any, are recorded as a component of interest expense and other expense, respectively.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company has not recorded any liabilities for uncertain tax positions or any related interest and penalties at March 31, 2016 or December 31, 2015. The Company&#146;s United States tax returns are open to audit for the years ended December 31, 2012 to 2015. The returns for the Swiss subsidiary, Mymetics S.A., are open to audit for the years ended December 31, 2010 to 2015. The returns for the Netherlands subsidiaries, Bestewil B.V. and Mymetics B.V., are open to audit for the year ended December 31, 2015.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&#160;Basic earnings per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. For the quarters ended March 31, 2016 and 2015, options and convertible debt were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred under the treasury stock method.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">For the three months ended March 31, 2016, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 559,614,329 at March 31, 2016 includes 530,034,329 potential issuable shares related to convertible loans and 29,580,000 potential issuable shares related to outstanding not expired options granted to employees.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;&#160;&#160; For the three months ended March 31, 2015, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 494,877,358 at March 31, 2015 includes 474,027,358 potential issuable shares related to convertible loans, and 20,850,000 potential issuable shares related to outstanding stock options granted to employees.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying dividend, conversion and voting rights. No preferred shares are issued or outstanding at March 31, 2016 or December 31, 2015.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Compensation cost for all share-based payments is based on the estimated grant-date fair value. The Company amortizes stock compensation cost ratably over the requisite service period.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The issuance of common shares for services is recorded at the quoted price of the shares on the date the shares are issued. No shares were issued to individuals as fee for services rendered in the three months ended March 31, 2016 nor in the three months ended March 31, 2015.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">Stock compensation expense amounted to E28 and E15 during the three months periods ended March 31, 2016 and 2015, respectively, and is included in the statement of operations within general and administrative expenses.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%; background-color: white"> <tr style="background-color: #CCEEFF"> <td style="width: 7%"><font style="font-size: 8pt">&#160;Level 1- </font></td> <td style="width: 1%">&#160;</td> <td style="width: 92%"><font style="font-size: 8pt">Quoted prices in active markets for identical assets or liabilities.</font></td></tr> <tr> <td><font style="font-size: 8pt">&#160;Level 2- </font></td> <td>&#160;</td> <td><font style="font-size: 8pt">Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities</font></td></tr> <tr style="background-color: #CCEEFF"> <td><font style="font-size: 8pt">&#160;Level 3- </font></td> <td>&#160;</td> <td><font style="font-size: 8pt">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">The Company generally has the following financial instruments: cash, receivables, accounts payable, and notes payable. The carrying value of cash, receivables and accounts payable, approximates their fair value based on the short-term nature of these financial instruments. Management believes that it is not practicable to estimate the fair value of the notes payable due to the unique nature of these instruments.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;&#160;&#160; The Company derived 54% and 94% of revenue from its relationship with one collaborative partner during the three month periods ended March 31, 2016 and March 31, 2015, respectively. Furthermore, that same collaborative partner accounted for 68% of the receivables balance at December 31, 2015 and 38% of the receivables balance at March 31, 2016.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">An individual employed by the law firm that acts as the Company's general counsel is a member of the Board of Directors.&#160; The Company incurred professional fees to the counsel's law firm totaling E5 and E7 for the period of three months ended March 31, 2016 and 2015, respectively.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt">&#160;&#160; &#160; In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the fiscal and interim reporting periods beginning after December 15, 2017 using either of two methods:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 8pt">(i)&#160;&#160;</font></td> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font-size: 8pt">retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 8pt">(ii)&#160;&#160;</font></td> <td style="font: 8pt Times New Roman, Times, Serif"><font style="font-size: 8pt">retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09.</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;&#160;Management is currently evaluating the impact of the Company's pending adoption of ASU 2014-09 on its consolidated financial statements.</p> 5000 7000 303757622 303757622 530034329 474027358 29580000 20850000 EX-101.SCH 6 mymx-20160331.xsd 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - 1. The Company and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 2. Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 3. Debt Financing link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 1. The Company and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 3. Debt Financing (Tables) link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 1. The Company and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mymx-20160331_cal.xml EX-101.DEF 8 mymx-20160331_def.xml EX-101.LAB 9 mymx-20160331_lab.xml Convertible loans Antidilutive Securities [Axis] Stock options granted to employees Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Trading Symbol Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Amendment Flag Document Period End Date Statement of Financial Position [Abstract] ASSETS Current Assets Cash Receivables Prepaid expenses Total current assets Property and equipment, net of accumulated depreciation of E324 at March 31, 2016 and E314 at December 31, 2015 In-process research and development Goodwill Total assets LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable Deferred revenue from grants Convertible notes payable to related parties Total liabilities Shareholders' Equity (Deficit) Common stock, U.S. $0.01 par value; 1,000,000,000 shares authorized; issued 303,757,622 at March 31, 2016 and at December 31, 2015 Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none issued or outstanding Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Total shareholders' equity (deficit) Total liabilities and shareholders' equity (deficit) Property and equipment, accumulated depreciation Common stock, par value (in dollars per share) Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Preferred stock, par value (in dollars per share) Preferred stock, shares authorized (in shares) Preferred stock, shares issued (in shares) Preferred stock, shares outstanding (in shares) Income Statement [Abstract] Revenue Research and development services Grants Total revenue Expenses Research and development General and administrative Bank fee Depreciation Directors' fees Foreign exchange and other Total expenses Operating (Loss) Income Interest expense Loss before income tax (provision) benefit Income tax (provision) benefit Net loss Other comprehensive loss Foreign currency translation adjustment Comprehensive loss Basic earnings per share Diluted earnings per share Statement of Cash Flows [Abstract] Cash Flow from Operating Activities Net loss Adjustments to reconcile net loss to net cash provided (used in) by operating activities Stock compensation expense - options Changes in operating assets and liabilities Receivables Accrued interests on notes payable Accounts payable Deferred revenue from grants Other Net cash (used in) provided by operating activities Cash Flows from Investing Activities Purchase of property and equipment Net cash used in investing activities Cash Flows from Financing Activities Payments on notes payable and other short-term advances Net cash used in financing activities Effect on foreign exchange rate on cash Net change in cash Cash, beginning of period Cash, end of period Supplemental Disclosure of Cash Flow Information: Cash Paid for Interest Supplemental Disclosure of Non-cash Financing Activities: Issuance of 5,338,809 shares of common stock to settle acquisition-Related contingent consideration Organization, Consolidation and Presentation of Financial Statements [Abstract] The Company and Summary of Significant Accounting Policies Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets Debt Disclosure [Abstract] Debt Financing BASIS OF PRESENTATION PRINCIPLES OF CONSOLIDATION FOREIGN CURRENCY TRANSLATION CASH REVENUE RECOGNITION RECEIVABLES PROPERTY AND EQUIPMENT IN-PROCESS RESEARCH AND DEVELOPMENT IMPAIRMENT OF LONG LIVED ASSETS GOODWILL CONTINGENT CONSIDERATION RESEARCH AND DEVELOPMENT TAXES ON INCOME EARNINGS PER SHARE PREFERRED STOCK STOCK-BASED COMPENSATION ESTIMATES FAIR VALUE MEASUREMENTS FAIR VALUES OF FINANCIAL INSTRUMENTS CONCENTRATIONS RELATED PARTY TRANSACTIONS NEW ACCOUNTING PRONOUNCEMENTS Convertible notes, loans and contingent liabilities Statement [Table] Statement [Line Items] Potential number of shares issuable Stock compensation expense Professional fees incurred and paid to a related party Bank fees. Disclosure of accounting policy for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Assets, Current Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Revenues Foreign Currency Transaction Gain (Loss), before Tax Costs and Expenses Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income Tax Expense (Benefit) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Increase (Decrease) in Receivables Increase (Decrease) in Accounts Payable Increase (Decrease) in Deferred Revenue Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Short-term Debt Cash, Period Increase (Decrease) EX-101.PRE 10 mymx-20160331_pre.xml XML 11 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
May. 12, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name MYMETICS CORP  
Entity Central Index Key 0000927761  
Current Fiscal Year End Date --12-31  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Filer Category Smaller Reporting Company  
Trading Symbol MYMX  
Entity Common Stock, Shares Outstanding   303,757,622
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q1  
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2016  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED BALANCE SHEETS (UNAUDITED) - EUR (€)
€ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current Assets    
Cash € 1,997 € 2,381
Receivables 112 218
Prepaid expenses 87 66
Total current assets 2,196 2,665
Property and equipment, net of accumulated depreciation of E324 at March 31, 2016 and E314 at December 31, 2015 96 106
In-process research and development 2,266 2,266
Goodwill 6,671 6,671
Total assets 11,229 11,708
Current Liabilities    
Accounts payable 145 416
Deferred revenue from grants 828 1,014
Convertible notes payable to related parties 43,719 43,170
Total liabilities 44,692 44,600
Shareholders' Equity (Deficit)    
Common stock, U.S. $0.01 par value; 1,000,000,000 shares authorized; issued 303,757,622 at March 31, 2016 and at December 31, 2015 2,530 2,530
Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none issued or outstanding 0 0
Additional paid-in capital 34,343 34,315
Accumulated deficit (71,020) (70,427)
Accumulated other comprehensive income 684 690
Total shareholders' equity (deficit) (33,463) (32,892)
Total liabilities and shareholders' equity (deficit) € 11,229 € 11,708
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)
€ in Thousands
Mar. 31, 2016
EUR (€)
shares
Mar. 31, 2016
$ / shares
Dec. 31, 2015
EUR (€)
shares
Dec. 31, 2015
$ / shares
ASSETS        
Property and equipment, accumulated depreciation | € € 324   € 314  
Shareholders' Equity (Deficit)        
Common stock, par value (in dollars per share) | $ / shares   $ .01   $ .01
Common stock, shares authorized (in shares) 1,000,000,000   1,000,000,000  
Common stock, shares issued (in shares) 303,757,622   303,757,622  
Preferred stock, par value (in dollars per share) | $ / shares   $ .01   $ .01
Preferred stock, shares authorized (in shares) 5,000,000   5,000,000  
Preferred stock, shares issued (in shares) 0   0  
Preferred stock, shares outstanding (in shares) 0   0  
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - EUR (€)
€ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenue    
Research and development services € 219 € 610
Grants 186 52
Total revenue 405 662
Expenses    
Research and development 109 367
General and administrative 343 393
Bank fee 1 1
Depreciation 10 10
Directors' fees 5 5
Foreign exchange and other (92) 193
Total expenses 376 969
Operating (Loss) Income 29 (307)
Interest expense 642 643
Loss before income tax (provision) benefit (613) (950)
Income tax (provision) benefit 20 (3)
Net loss (593) (953)
Other comprehensive loss    
Foreign currency translation adjustment (6) 63
Comprehensive loss € (599) € (890)
Basic earnings per share € 0.00 € 0.00
Diluted earnings per share € 0.00 € 0.00
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - EUR (€)
€ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash Flow from Operating Activities    
Net loss € (593) € (953)
Adjustments to reconcile net loss to net cash provided (used in) by operating activities    
Depreciation 10 10
Stock compensation expense - options 28 15
Changes in operating assets and liabilities    
Receivables 106 (21)
Accrued interests on notes payable 549 877
Accounts payable (271) 112
Deferred revenue from grants (186) 0
Other (21) (1)
Net cash (used in) provided by operating activities (378) 39
Cash Flows from Investing Activities    
Purchase of property and equipment 0 (7)
Net cash used in investing activities 0 (7)
Cash Flows from Financing Activities    
Net cash used in financing activities 0 0
Effect on foreign exchange rate on cash (6) 63
Net change in cash (384) 95
Cash, beginning of period 2,381 1,614
Cash, end of period € 1,997 € 1,709
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
1. The Company and Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company and Summary of Significant Accounting Policies

BASIS OF PRESENTATION

 

The amounts in the notes are shown in thousands of EURO rounded to the nearest thousand except for share and per share amounts.

 

The accompanying interim period consolidated financial statements of Mymetics Corporation (the "Company") set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2015.

 

The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three-month period ending March 31, 2016 were of a normal and recurring nature.

 

Mymetics Corporation (the "Company" or "Mymetics") was created for the purpose of engaging in vaccine research and development. Its main research efforts in the beginning have been concentrated in the prevention and treatment of the AIDS virus and malaria and has later expanded to other vaccines for infectious diseases since the acquisition of Bestewil Holding BV in April 2009. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. The Company has the following vaccines under development; (i) Herpes Simplex which is at the pre-clinical stage and currently on hold, (ii) intranasal influenza which has finished a clinical trial Phase I for which the Company is seeking partners (iii) Respiratory Syncytial Virus (RSV) which is at the pre-clinical stage, (iv) HIV-1 which has finished a Phase I and is currently in a repeat non-human primate study with the Texas Biomedical Research Institute, (v) malaria, which has finished a Phase Ib and a malaria transmission blocking vaccine which is in pre-clinical study with PATH-MVI and LMIV and (vi) two vaccine candidates that are currently in a discovery phase, one for Chikungunya and one for Zika.

 

As of March 31, 2016, the Company is in the pre-clinical testing of some of its vaccine candidates and a commercially viable product is not expected for several more years. However, the Company generates some revenue through the licensing of its RSV vaccine and from collaboration and grant agreements for R&D services. Management believes that the Company’s research and development activities will result in valuable intellectual property that can generate significant revenues in the future such as by licensing. Vaccines are one of the fastest growing markets in the pharmaceutical industry.

 

These consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced significant losses since inception resulting in an accumulated deficit of E71,020 at March 31, 2016. Further, the Company’s current liabilities exceed its current assets by E42,496 as of March 31, 2016, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts. These conditions raise substantial doubt about our ability to continue as a going concern.

  

PRINCIPLES OF CONSOLIDATION

 

The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated.

 

FOREIGN CURRENCY TRANSLATION

 

The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.

 

CASH

 

Cash deposits are occasionally in excess of insured amounts.

 

REVENUE RECOGNITION

 

Exclusive Licenses

 

The deliverables under an exclusive license agreement generally include the exclusive license to the Company’s technology, and may also include deliverables related to research activities to be performed on behalf of the collaborative collaborator and the manufacture of preclinical or clinical materials for the collaborative collaborator.

 

Generally, exclusive license agreements contain non-refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) provide research services which are reimbursed at a contractually determined rate which includes margin for the Company, (ii) participate in a joint steering committee to monitor the progress of the research and development which will be reimbursed at a contractually determined rate which includes margin for the Company, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments at the time of commercialization until the later of expiration of the last to expire valid patent rights expire or 10 years after the first commercial sale. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements.  The Company does not directly control when any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments.  As a result, the Company cannot predict when it will recognize revenues in connection with any of the foregoing.

 

The Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, "Revenue Recognition—Multiple-Element Arrangements," and ASC Topic 605-28, "Revenue Recognition—Milestone Method," in accounting for these agreements.  In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the collaborator.  The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Factors considered in this determination include the research and manufacturing capabilities of the collaborator and the availability of technology research expertise in the general marketplace

 

RSV Corporation

 

In December 2013, the Company entered into an agreement with RSV Corporation. The agreement provided RSV Corporation with an exclusive license to the Company’s RSV technology in order to develop and commercialize respiratory syncytial virus virosome vaccines. The Company received a US$5 million upfront payment in connection with the execution of the agreement and the Company was entitled to receive milestone payments potentially totaling $77 million plus royalties on product sales, if any. The Company also was entitled to receive payments for research and development activities performed on behalf of RSV Corporation. RSV Corporation was responsible for the development, manufacturing, and marketing of any products resulting from this agreement.

 

In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the agreement. The significant deliverables were determined to be the RSV technology license and the research and development services including participation on the Joint Collaboration and Steering Committee (JCSC). The Company determined that the RSV technology license had standalone value from the research services. As a result, the research services were considered a separate unit of accounting. The estimated selling prices for these units of accounting were determined based on market conditions and entity-specific factors such as the terms of the collaborators’ previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company’s RSV technology, the Company’s pricing practices and pricing objectives, and the nature of the research services to be performed for RSV Corporation and market rates for similar services. The arrangement consideration was allocated to the deliverables based on the relative selling price method. The Company recognized license revenue when the exclusive license was delivered pursuant to the terms of the agreement which was upon execution of the agreement. The Company recognized research services revenue as the related services were delivered.

 

  On January 25, 2016 Mymetics received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious therapies. The LCA which was signed on December 27, 2013, between Bestewil Holding BV and RSVC will formally be terminated as of July 25, 2016.

 

Fixed price contracts and research and collaboration agreements

 

When the performance under a fixed price contract can be reasonably estimated, revenue for such a contract is recognized under the proportional performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses. If the performance under a fixed price contract cannot be reasonably estimated, the Company recognizes the revenue on a straight-line basis over the contract term.

 

TEXAS BIOMEDICAL RESEARCH INSTITUTE

 

 In September 2014, the Company entered into a material transfer agreement and fixed price contract with Texas Biomedical Research Institute. The agreement provides Texas Biomedical Research Institute the lead of a project which has been proposed to the Bill and Melinda Gates foundation with the objective to confirm previous results obtained in non-human primates with these virosome based HIV vaccine candidates. The Company has tested these different formulations of virosome based HIV vaccines candidates in preclinical non-human primate studies and in Phase I clinical settings. The Company produced and transferred to Texas Biomedical Research Institute the original material using the Company’s background IP. Results of the project with Texas Biomedical Research Institute was received in April 2016 (see note on subsequent events). The Company recognizes revenue under the proportional performance method.

 

PATH-MVI

 

In November 2014, the Company signed an agreement with PATH Malaria Vaccine Initiative (MVI) and the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), where Mymetics has developed and produced virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate which are based on two antigens provided by LMIV. The vaccine formulations were then tested in animal models. PATH MVI funded all activities under this project, which started in January 2015 and ended in January 2016. The Company has recognized revenue under the proportional performance method.

 

HORIZON 2020

 

In April 2015, the Company was selected to receive project grants with a total of E8.4 million. A total of E5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program and up to E3.1 million of funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The grant funds the evaluation, development and manufacturing scale-up of thermo-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Of the total amount, E3.4 million is directly attributable to Mymetics activities, with the remaining balance going to the consortium partners. The project duration is 42 months and started on May 4, 2015. In May 2015, the Company received a pre-payment from the two granting organizations for a total value of E1.5 million. The pre-payment has been recorded as a current liability and revenue has been recognized as services are delivered.

 

RECEIVABLES

 

Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. There was no allowance necessary at March 31, 2016 or December 31, 2015. The Company charges off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.

 

PROPERTY AND EQUIPMENT

 

Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.

 

IN-PROCESS RESEARCH AND DEVELOPMENT

 

In-process research and development (referred to as IPR&D) represents the estimated fair value assigned to research and development projects acquired in a purchased business combination that have not been completed at the date of acquisition and which have no alternative future use. IPR&D assets acquired in a business combination are capitalized as indefinite-lived intangible assets. These assets remain indefinite-lived until the completion or abandonment of the associated research and development efforts. During the periods prior to completion or abandonment, those acquired indefinite-lived assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired.

 

IMPAIRMENT OF LONG LIVED ASSETS

 

Long-lived assets, which include property and equipment, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income in the period that the impairment occurs.

 

GOODWILL

 

 Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis as of April 1 of each year, unless events or circumstances indicate impairment may have occurred before that time. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. After assessing qualitative factors, the Company must determine if further testing was necessary. If further testing was necessary, the Company would have performed a two-step impairment test for goodwill. The first step requires the Company to determine the fair value of each reporting unit. To the extent a reporting unit’s carrying amount exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company must perform a second more detailed impairment assessment. The second impairment assessment involves allocating the reporting unit’s fair value to all of its recognized and unrecognized assets and liabilities in order to determine the implied fair value of the reporting unit’s goodwill as of the assessment date. The implied fair value of the reporting unit’s goodwill is then compared to the carrying amount of goodwill to quantify an impairment charge as of the assessment date.

 

The Company has conducted its impairment testing as of April 1, of 2016 and 2015 of its goodwill recognized in connection to the acquisition of Bestewil. In conclusion of this impairment testing, the carrying amount of the reporting unit was lower than the estimated fair value of the reporting unit. As the fair value of the reporting unit is higher than the carrying amount, Step 2 of the goodwill impairment test did not need to be completed. As of March 31, 2016, management believes there are no indications of impairment.

 

RESEARCH AND DEVELOPMENT

 

Research and development costs are expensed as incurred.

 

TAXES ON INCOME

 

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.

 

The Company reports a liability, if any, for unrecognized tax benefits resulting from uncertain income tax positions taken or expected to be taken in an income tax return. Estimated interest and penalties, if any, are recorded as a component of interest expense and other expense, respectively.

 

The Company has not recorded any liabilities for uncertain tax positions or any related interest and penalties at March 31, 2016 or December 31, 2015. The Company’s United States tax returns are open to audit for the years ended December 31, 2012 to 2015. The returns for the Swiss subsidiary, Mymetics S.A., are open to audit for the years ended December 31, 2010 to 2015. The returns for the Netherlands subsidiaries, Bestewil B.V. and Mymetics B.V., are open to audit for the year ended December 31, 2015.

 

 

EARNINGS PER SHARE

 

 Basic earnings per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. For the quarters ended March 31, 2016 and 2015, options and convertible debt were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred under the treasury stock method.

 

For the three months ended March 31, 2016, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 559,614,329 at March 31, 2016 includes 530,034,329 potential issuable shares related to convertible loans and 29,580,000 potential issuable shares related to outstanding not expired options granted to employees.

 

    For the three months ended March 31, 2015, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 494,877,358 at March 31, 2015 includes 474,027,358 potential issuable shares related to convertible loans, and 20,850,000 potential issuable shares related to outstanding stock options granted to employees.

  

PREFERRED STOCK

 

The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying dividend, conversion and voting rights. No preferred shares are issued or outstanding at March 31, 2016 or December 31, 2015.

 

STOCK-BASED COMPENSATION

 

 Compensation cost for all share-based payments is based on the estimated grant-date fair value. The Company amortizes stock compensation cost ratably over the requisite service period.

 

The issuance of common shares for services is recorded at the quoted price of the shares on the date the shares are issued. No shares were issued to individuals as fee for services rendered in the three months ended March 31, 2016 nor in the three months ended March 31, 2015.

 

Stock compensation expense amounted to E28 and E15 during the three months periods ended March 31, 2016 and 2015, respectively, and is included in the statement of operations within general and administrative expenses.

 

ESTIMATES

 

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

FAIR VALUE MEASUREMENTS

 

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

 

 Level 1-   Quoted prices in active markets for identical assets or liabilities.
 Level 2-   Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
 Level 3-   Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

FAIR VALUES OF FINANCIAL INSTRUMENTS

 

The Company generally has the following financial instruments: cash, receivables, accounts payable, and notes payable. The carrying value of cash, receivables and accounts payable, approximates their fair value based on the short-term nature of these financial instruments. Management believes that it is not practicable to estimate the fair value of the notes payable due to the unique nature of these instruments.

 

CONCENTRATIONS

 

    The Company derived 54% and 94% of revenue from its relationship with one collaborative partner during the three month periods ended March 31, 2016 and March 31, 2015, respectively. Furthermore, that same collaborative partner accounted for 68% of the receivables balance at December 31, 2015 and 38% of the receivables balance at March 31, 2016.

 

RELATED PARTY TRANSACTIONS

 

An individual employed by the law firm that acts as the Company's general counsel is a member of the Board of Directors.  The Company incurred professional fees to the counsel's law firm totaling E5 and E7 for the period of three months ended March 31, 2016 and 2015, respectively.

 

NEW ACCOUNTING PRONOUNCEMENTS

 

     In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the fiscal and interim reporting periods beginning after December 15, 2017 using either of two methods:

 

(i)   retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or

 

(ii)   retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09.

 

  Management is currently evaluating the impact of the Company's pending adoption of ASU 2014-09 on its consolidated financial statements.

XML 17 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
2. Intangible Assets
3 Months Ended
Mar. 31, 2016
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Intangible Assets

Intangible assets consisted of in process research and development at March 31, 2016 and December 31, 2015.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
3. Debt Financing
3 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Debt Financing

Certain principal shareholders have granted the Company secured convertible notes (in accordance with the Uniform Commercial Code in the State of Delaware) and short term convertible notes, which have a total carrying value of E43,719 including interest due to date. Interest incurred on these notes since inception has been added to the principal amounts.

 

   The details of the convertible notes and loans are as follows at March 31, 2016:

 

                          Fixed  
                    Conversion     Rate  
Lender 1st-Issue   Principal     Duration   Interest   Price     EUR/USD  
Price Date   Amount     (Note)   Rate   (stated)     Conversion  
                             
Eardley Holding A.G. (1) 06/23/2006    E 167       (2 ) 10% pa   $ 0.10       N/A  
Anglo Irish Bank S.A.(3) 10/21/2007    E 500       (2 ) 10% pa   $ 0.50       1.4090  
Round Enterprises Ltd. 12/10/2007    E 1,500       (2 ) 10% pa   $ 0.50       1.4429  
Round Enterprises Ltd. 01/22/2008    E 1,500       (2 ) 10% pa   $ 0.50       1.4629  
Round Enterprises Ltd. 04/25/2008    E 2,000       (2 ) 10% pa   $ 0.50       1.5889  
Round Enterprises Ltd. 06/30/2008    E 1,500       (2 ) 10% pa   $ 0.50       1.5380  
Round Enterprises Ltd. 11/18/2008    E 1,200       (2 ) 10% pa   $ 0.50       1.2650  
Round Enterprises Ltd. 02/09/2009    E 1,500       (2 ) 10% pa   $ 0.50       1.2940  
Round Enterprises Ltd. 06/15/2009    E 5,500       (2,4 ) 10% pa   $ 0.80       1.4045  
Eardley Holding A.G. 06/15/2009    E 100       (2,4 ) 10% pa   $ 0.80       1.4300  
Von Meyenburg 08/03/2009    E 200       (2 ) 10% pa   $ 0.80       1.4400  
Round Enterprises Ltd. 10/13/2009    E 2,000       (2 ) 5% pa   $ 0.25       1.4854  
Round Enterprises Ltd. 12/18/2009    E 2,200       (2 ) 5% pa   $ 0.25       1.4338  
Round Enterprises Ltd. 08/04/2011    E 1,057       (5,6 ) 10% pa   $ 0.034       N/A  
Eardley Holding A.G. 08/04/2011    E 264       (5,6 ) 10% pa   $ 0.034       N/A  
Round Enterprises Ltd. 11/08/2011    E 400       (6 ) 10% pa   $ 0.034       1.3787  
Eardley Holding A.G. 11/08/2011    E 100       (6 ) 10% pa   $ 0.034       1.3787  
Round Enterprises Ltd. 02/10/2012    E 1,000       (6 ) 10% pa   $ 0.034       1.3260  
Eardley Holding A.G. 02/14/2012    E 200       (6 ) 10% pa   $ 0.034       1.3260  
Round Enterprises Ltd. 04/19/2012    E 322       (6 ) 10% pa   $ 0.034       1.3100  
Eardley Holding A.G. 04/19/2012    E 80       (6 ) 10% pa   $ 0.034       1.3100  
Round Enterprises Ltd. 05/04/2012    E 480       (6 ) 10% pa   $ 0.034       1.3152  
Eardley Holding A.G. 05/04/2012    E 120       (6 ) 10% pa   $ 0.034       1.3152  
Round Enterprises Ltd. 09/03/2012    E 200       (6 ) 10% pa   $ 0.034       1.2576  
Eardley Holding A.G. 09/03/2012    E 50       (6 ) 10% pa   $ 0.034       1.2576  
Round Enterprises Ltd. 11/14/2012    E 500       (6 ) 10% pa   $ 0.034       1.2718  
Eardley Holding A.G. 12/06/2012    E 125       (6 ) 10% pa   $ 0.034       1.3070  
Round Enterprises Ltd. 01/16/2013    E 240       (6 ) 10% pa   $ 0.034       1.3318  
Eardley Holding A.G. 01/16/2013    E 60       (6 ) 10% pa   $ 0.034       1.3318  
Round Enterprises Ltd. 03/25/2013    E 400       (6 ) 10% pa   $ 0.037       1.2915  
Eardley Holding A.G. 04/14/2013    E 150       (6 ) 10% pa   $ 0.034       1.3056  
Round Enterprises Ltd. 04/14/2013    E 600       (6 ) 10% pa   $ 0.034       1.3056  
Eardley Holding A.G. 05/15/2013    E 170       (6 ) 10% pa   $ 0.037       1.2938  
Round Enterprises Ltd. 05/15/2013    E 680       (6 ) 10% pa   $ 0.037       1.2938  
Eardley Holding A.G. 06/24/2013    E 60       (6 ) 10% pa   $ 0.025       1.3340  
Round Enterprises Ltd. 06/24/2013    E 240       (6 ) 10% pa   $ 0.025       1.3340  
Eardley Holding A.G. 08/05/2013    E 80       (6 ) 10% pa   $ 0.018       1.3283  
Round Enterprises Ltd. 08/05/2013    E 320       (6 ) 10% pa   $ 0.018       1.3283  
Total Short Term Principal Amounts      E 27,765                            
   Accrued Interest      E 15,954                            
                                     
TOTAL LOANS AND NOTES      E 43,719                            

 

(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

 

(2) This maturity date is automatically prolonged for periods of three months, unless called for repayment.

 

(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

 

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.

 

(5) The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively.

 

(6) This maturity date is automatically prolonged for periods of three months, unless called for repayment. The conversion price per share is determined by the lower of (i) reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than US$20,000, or (ii) at the stated conversion price using a fixed exchange rate which are noted in the table above.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
1. The Company and Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION

The amounts in the notes are shown in thousands of EURO rounded to the nearest thousand except for share and per share amounts.

 

The accompanying interim period consolidated financial statements of Mymetics Corporation (the "Company") set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2015.

 

The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three-month period ending March 31, 2016 were of a normal and recurring nature.

 

Mymetics Corporation (the "Company" or "Mymetics") was created for the purpose of engaging in vaccine research and development. Its main research efforts in the beginning have been concentrated in the prevention and treatment of the AIDS virus and malaria and has later expanded to other vaccines for infectious diseases since the acquisition of Bestewil Holding BV in April 2009. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. The Company has the following vaccines under development; (i) Herpes Simplex which is at the pre-clinical stage and currently on hold, (ii) intranasal influenza which has finished a clinical trial Phase I for which the Company is seeking partners (iii) Respiratory Syncytial Virus (RSV) which is at the pre-clinical stage, (iv) HIV-1 which has finished a Phase I and is currently in a repeat non-human primate study with the Texas Biomedical Research Institute, (v) malaria, which has finished a Phase Ib and a malaria transmission blocking vaccine which is in pre-clinical study with PATH-MVI and LMIV and (vi) two vaccine candidates that are currently in a discovery phase, one for Chikungunya and one for Zika.

 

As of March 31, 2016, the Company is in the pre-clinical testing of some of its vaccine candidates and a commercially viable product is not expected for several more years. However, the Company generates some revenue through the licensing of its RSV vaccine and from collaboration and grant agreements for R&D services. Management believes that the Company’s research and development activities will result in valuable intellectual property that can generate significant revenues in the future such as by licensing. Vaccines are one of the fastest growing markets in the pharmaceutical industry.

 

These consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has experienced significant losses since inception resulting in an accumulated deficit of E71,020 at March 31, 2016. Further, the Company’s current liabilities exceed its current assets by E42,496 as of March 31, 2016, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts. These conditions raise substantial doubt about our ability to continue as a going concern.

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated.

FOREIGN CURRENCY TRANSLATION

The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.

CASH

Cash deposits are occasionally in excess of insured amounts.

REVENUE RECOGNITION

Exclusive Licenses

 

The deliverables under an exclusive license agreement generally include the exclusive license to the Company’s technology, and may also include deliverables related to research activities to be performed on behalf of the collaborative collaborator and the manufacture of preclinical or clinical materials for the collaborative collaborator.

 

Generally, exclusive license agreements contain non-refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) provide research services which are reimbursed at a contractually determined rate which includes margin for the Company, (ii) participate in a joint steering committee to monitor the progress of the research and development which will be reimbursed at a contractually determined rate which includes margin for the Company, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments at the time of commercialization until the later of expiration of the last to expire valid patent rights expire or 10 years after the first commercial sale. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements.  The Company does not directly control when any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments.  As a result, the Company cannot predict when it will recognize revenues in connection with any of the foregoing.

 

The Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, "Revenue Recognition—Multiple-Element Arrangements," and ASC Topic 605-28, "Revenue Recognition—Milestone Method," in accounting for these agreements.  In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the collaborator.  The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Factors considered in this determination include the research and manufacturing capabilities of the collaborator and the availability of technology research expertise in the general marketplace

 

RSV Corporation

 

In December 2013, the Company entered into an agreement with RSV Corporation. The agreement provided RSV Corporation with an exclusive license to the Company’s RSV technology in order to develop and commercialize respiratory syncytial virus virosome vaccines. The Company received a US$5 million upfront payment in connection with the execution of the agreement and the Company was entitled to receive milestone payments potentially totaling $77 million plus royalties on product sales, if any. The Company also was entitled to receive payments for research and development activities performed on behalf of RSV Corporation. RSV Corporation was responsible for the development, manufacturing, and marketing of any products resulting from this agreement.

 

In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the agreement. The significant deliverables were determined to be the RSV technology license and the research and development services including participation on the Joint Collaboration and Steering Committee (JCSC). The Company determined that the RSV technology license had standalone value from the research services. As a result, the research services were considered a separate unit of accounting. The estimated selling prices for these units of accounting were determined based on market conditions and entity-specific factors such as the terms of the collaborators’ previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company’s RSV technology, the Company’s pricing practices and pricing objectives, and the nature of the research services to be performed for RSV Corporation and market rates for similar services. The arrangement consideration was allocated to the deliverables based on the relative selling price method. The Company recognized license revenue when the exclusive license was delivered pursuant to the terms of the agreement which was upon execution of the agreement. The Company recognized research services revenue as the related services were delivered.

 

  On January 25, 2016 Mymetics received notice from RSV Corporation (RSVC) that it will no longer pursue the development of a vaccine technology for Respiratory Syncytial Virus (RSV) in order to focus on other infectious therapies. The LCA which was signed on December 27, 2013, between Bestewil Holding BV and RSVC will formally be terminated as of July 25, 2016.

 

Fixed price contracts and research and collaboration agreements

 

When the performance under a fixed price contract can be reasonably estimated, revenue for such a contract is recognized under the proportional performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses. If the performance under a fixed price contract cannot be reasonably estimated, the Company recognizes the revenue on a straight-line basis over the contract term.

 

TEXAS BIOMEDICAL RESEARCH INSTITUTE

 

 In September 2014, the Company entered into a material transfer agreement and fixed price contract with Texas Biomedical Research Institute. The agreement provides Texas Biomedical Research Institute the lead of a project which has been proposed to the Bill and Melinda Gates foundation with the objective to confirm previous results obtained in non-human primates with these virosome based HIV vaccine candidates. The Company has tested these different formulations of virosome based HIV vaccines candidates in preclinical non-human primate studies and in Phase I clinical settings. The Company produced and transferred to Texas Biomedical Research Institute the original material using the Company’s background IP. Results of the project with Texas Biomedical Research Institute was received in April 2016 (see note on subsequent events). The Company recognizes revenue under the proportional performance method.

 

PATH-MVI

 

In November 2014, the Company signed an agreement with PATH Malaria Vaccine Initiative (MVI) and the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), where Mymetics has developed and produced virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate which are based on two antigens provided by LMIV. The vaccine formulations were then tested in animal models. PATH MVI funded all activities under this project, which started in January 2015 and ended in January 2016. The Company has recognized revenue under the proportional performance method.

 

HORIZON 2020

 

In April 2015, the Company was selected to receive project grants with a total of E8.4 million. A total of E5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program and up to E3.1 million of funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The grant funds the evaluation, development and manufacturing scale-up of thermo-stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Of the total amount, E3.4 million is directly attributable to Mymetics activities, with the remaining balance going to the consortium partners. The project duration is 42 months and started on May 4, 2015. In May 2015, the Company received a pre-payment from the two granting organizations for a total value of E1.5 million. The pre-payment has been recorded as a current liability and revenue has been recognized as services are delivered.

RECEIVABLES

Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. There was no allowance necessary at March 31, 2016 or December 31, 2015. The Company charges off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.

PROPERTY AND EQUIPMENT

Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.

IN-PROCESS RESEARCH AND DEVELOPMENT

In-process research and development (referred to as IPR&D) represents the estimated fair value assigned to research and development projects acquired in a purchased business combination that have not been completed at the date of acquisition and which have no alternative future use. IPR&D assets acquired in a business combination are capitalized as indefinite-lived intangible assets. These assets remain indefinite-lived until the completion or abandonment of the associated research and development efforts. During the periods prior to completion or abandonment, those acquired indefinite-lived assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired.

IMPAIRMENT OF LONG LIVED ASSETS

Long-lived assets, which include property and equipment, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income in the period that the impairment occurs.

GOODWILL

 Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis as of April 1 of each year, unless events or circumstances indicate impairment may have occurred before that time. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. After assessing qualitative factors, the Company must determine if further testing was necessary. If further testing was necessary, the Company would have performed a two-step impairment test for goodwill. The first step requires the Company to determine the fair value of each reporting unit. To the extent a reporting unit’s carrying amount exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company must perform a second more detailed impairment assessment. The second impairment assessment involves allocating the reporting unit’s fair value to all of its recognized and unrecognized assets and liabilities in order to determine the implied fair value of the reporting unit’s goodwill as of the assessment date. The implied fair value of the reporting unit’s goodwill is then compared to the carrying amount of goodwill to quantify an impairment charge as of the assessment date.

 

The Company has conducted its impairment testing as of April 1, of 2016 and 2015 of its goodwill recognized in connection to the acquisition of Bestewil. In conclusion of this impairment testing, the carrying amount of the reporting unit was lower than the estimated fair value of the reporting unit. As the fair value of the reporting unit is higher than the carrying amount, Step 2 of the goodwill impairment test did not need to be completed. As of March 31, 2016, management believes there are no indications of impairment.

RESEARCH AND DEVELOPMENT

Research and development costs are expensed as incurred.

TAXES ON INCOME

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.

 

The Company reports a liability, if any, for unrecognized tax benefits resulting from uncertain income tax positions taken or expected to be taken in an income tax return. Estimated interest and penalties, if any, are recorded as a component of interest expense and other expense, respectively.

 

The Company has not recorded any liabilities for uncertain tax positions or any related interest and penalties at March 31, 2016 or December 31, 2015. The Company’s United States tax returns are open to audit for the years ended December 31, 2012 to 2015. The returns for the Swiss subsidiary, Mymetics S.A., are open to audit for the years ended December 31, 2010 to 2015. The returns for the Netherlands subsidiaries, Bestewil B.V. and Mymetics B.V., are open to audit for the year ended December 31, 2015.

EARNINGS PER SHARE

 Basic earnings per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. For the quarters ended March 31, 2016 and 2015, options and convertible debt were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred under the treasury stock method.

 

For the three months ended March 31, 2016, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 559,614,329 at March 31, 2016 includes 530,034,329 potential issuable shares related to convertible loans and 29,580,000 potential issuable shares related to outstanding not expired options granted to employees.

 

    For the three months ended March 31, 2015, the basic weighted average number of shares was 303,757,622. The total potential number of shares issuable of 494,877,358 at March 31, 2015 includes 474,027,358 potential issuable shares related to convertible loans, and 20,850,000 potential issuable shares related to outstanding stock options granted to employees.

PREFERRED STOCK

The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying dividend, conversion and voting rights. No preferred shares are issued or outstanding at March 31, 2016 or December 31, 2015.

STOCK-BASED COMPENSATION

Compensation cost for all share-based payments is based on the estimated grant-date fair value. The Company amortizes stock compensation cost ratably over the requisite service period.

 

The issuance of common shares for services is recorded at the quoted price of the shares on the date the shares are issued. No shares were issued to individuals as fee for services rendered in the three months ended March 31, 2016 nor in the three months ended March 31, 2015.

 

Stock compensation expense amounted to E28 and E15 during the three months periods ended March 31, 2016 and 2015, respectively, and is included in the statement of operations within general and administrative expenses.

ESTIMATES

The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

FAIR VALUE MEASUREMENTS

Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

 

 Level 1-   Quoted prices in active markets for identical assets or liabilities.
 Level 2-   Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
 Level 3-   Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

FAIR VALUES OF FINANCIAL INSTRUMENTS

The Company generally has the following financial instruments: cash, receivables, accounts payable, and notes payable. The carrying value of cash, receivables and accounts payable, approximates their fair value based on the short-term nature of these financial instruments. Management believes that it is not practicable to estimate the fair value of the notes payable due to the unique nature of these instruments.

CONCENTRATIONS

    The Company derived 54% and 94% of revenue from its relationship with one collaborative partner during the three month periods ended March 31, 2016 and March 31, 2015, respectively. Furthermore, that same collaborative partner accounted for 68% of the receivables balance at December 31, 2015 and 38% of the receivables balance at March 31, 2016.

RELATED PARTY TRANSACTIONS

An individual employed by the law firm that acts as the Company's general counsel is a member of the Board of Directors.  The Company incurred professional fees to the counsel's law firm totaling E5 and E7 for the period of three months ended March 31, 2016 and 2015, respectively.

NEW ACCOUNTING PRONOUNCEMENTS

     In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the fiscal and interim reporting periods beginning after December 15, 2017 using either of two methods:

 

(i)   retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or

 

(ii)   retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09.

 

  Management is currently evaluating the impact of the Company's pending adoption of ASU 2014-09 on its consolidated financial statements.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
3. Debt Financing (Tables)
3 Months Ended
Mar. 31, 2016
Debt Disclosure [Abstract]  
Convertible notes, loans and contingent liabilities
                          Fixed  
                    Conversion     Rate  
Lender 1st-Issue   Principal     Duration   Interest   Price     EUR/USD  
Price Date   Amount     (Note)   Rate   (stated)     Conversion  
                             
Eardley Holding A.G. (1) 06/23/2006    E 167       (2 ) 10% pa   $ 0.10       N/A  
Anglo Irish Bank S.A.(3) 10/21/2007    E 500       (2 ) 10% pa   $ 0.50       1.4090  
Round Enterprises Ltd. 12/10/2007    E 1,500       (2 ) 10% pa   $ 0.50       1.4429  
Round Enterprises Ltd. 01/22/2008    E 1,500       (2 ) 10% pa   $ 0.50       1.4629  
Round Enterprises Ltd. 04/25/2008    E 2,000       (2 ) 10% pa   $ 0.50       1.5889  
Round Enterprises Ltd. 06/30/2008    E 1,500       (2 ) 10% pa   $ 0.50       1.5380  
Round Enterprises Ltd. 11/18/2008    E 1,200       (2 ) 10% pa   $ 0.50       1.2650  
Round Enterprises Ltd. 02/09/2009    E 1,500       (2 ) 10% pa   $ 0.50       1.2940  
Round Enterprises Ltd. 06/15/2009    E 5,500       (2,4 ) 10% pa   $ 0.80       1.4045  
Eardley Holding A.G. 06/15/2009    E 100       (2,4 ) 10% pa   $ 0.80       1.4300  
Von Meyenburg 08/03/2009    E 200       (2 ) 10% pa   $ 0.80       1.4400  
Round Enterprises Ltd. 10/13/2009    E 2,000       (2 ) 5% pa   $ 0.25       1.4854  
Round Enterprises Ltd. 12/18/2009    E 2,200       (2 ) 5% pa   $ 0.25       1.4338  
Round Enterprises Ltd. 08/04/2011    E 1,057       (5,6 ) 10% pa   $ 0.034       N/A  
Eardley Holding A.G. 08/04/2011    E 264       (5,6 ) 10% pa   $ 0.034       N/A  
Round Enterprises Ltd. 11/08/2011    E 400       (6 ) 10% pa   $ 0.034       1.3787  
Eardley Holding A.G. 11/08/2011    E 100       (6 ) 10% pa   $ 0.034       1.3787  
Round Enterprises Ltd. 02/10/2012    E 1,000       (6 ) 10% pa   $ 0.034       1.3260  
Eardley Holding A.G. 02/14/2012    E 200       (6 ) 10% pa   $ 0.034       1.3260  
Round Enterprises Ltd. 04/19/2012    E 322       (6 ) 10% pa   $ 0.034       1.3100  
Eardley Holding A.G. 04/19/2012    E 80       (6 ) 10% pa   $ 0.034       1.3100  
Round Enterprises Ltd. 05/04/2012    E 480       (6 ) 10% pa   $ 0.034       1.3152  
Eardley Holding A.G. 05/04/2012    E 120       (6 ) 10% pa   $ 0.034       1.3152  
Round Enterprises Ltd. 09/03/2012    E 200       (6 ) 10% pa   $ 0.034       1.2576  
Eardley Holding A.G. 09/03/2012    E 50       (6 ) 10% pa   $ 0.034       1.2576  
Round Enterprises Ltd. 11/14/2012    E 500       (6 ) 10% pa   $ 0.034       1.2718  
Eardley Holding A.G. 12/06/2012    E 125       (6 ) 10% pa   $ 0.034       1.3070  
Round Enterprises Ltd. 01/16/2013    E 240       (6 ) 10% pa   $ 0.034       1.3318  
Eardley Holding A.G. 01/16/2013    E 60       (6 ) 10% pa   $ 0.034       1.3318  
Round Enterprises Ltd. 03/25/2013    E 400       (6 ) 10% pa   $ 0.037       1.2915  
Eardley Holding A.G. 04/14/2013    E 150       (6 ) 10% pa   $ 0.034       1.3056  
Round Enterprises Ltd. 04/14/2013    E 600       (6 ) 10% pa   $ 0.034       1.3056  
Eardley Holding A.G. 05/15/2013    E 170       (6 ) 10% pa   $ 0.037       1.2938  
Round Enterprises Ltd. 05/15/2013    E 680       (6 ) 10% pa   $ 0.037       1.2938  
Eardley Holding A.G. 06/24/2013    E 60       (6 ) 10% pa   $ 0.025       1.3340  
Round Enterprises Ltd. 06/24/2013    E 240       (6 ) 10% pa   $ 0.025       1.3340  
Eardley Holding A.G. 08/05/2013    E 80       (6 ) 10% pa   $ 0.018       1.3283  
Round Enterprises Ltd. 08/05/2013    E 320       (6 ) 10% pa   $ 0.018       1.3283  
Total Short Term Principal Amounts      E 27,765                            
   Accrued Interest      E 15,954                            
                                     
TOTAL LOANS AND NOTES      E 43,719                            

 

(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

 

(2) This maturity date is automatically prolonged for periods of three months, unless called for repayment.

 

(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

 

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.

 

(5) The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively.

 

(6) This maturity date is automatically prolonged for periods of three months, unless called for repayment. The conversion price per share is determined by the lower of (i) reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than US$20,000, or (ii) at the stated conversion price using a fixed exchange rate which are noted in the table above.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
1. The Company and Summary of Significant Accounting Policies (Details Narrative) - EUR (€)
€ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Potential number of shares issuable 303,757,622 303,757,622
Stock compensation expense € 28 € 15
Professional fees incurred and paid to a related party € 5 € 7
Convertible loans    
Potential number of shares issuable 530,034,329 474,027,358
Stock options granted to employees    
Potential number of shares issuable 29,580,000 20,850,000
EXCEL 22 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +5VK$C7B+YI9 $ #P* 3 6T-O;G1E;G1?5'EP97-= M+GAM;,U674_",!3]*V2OAA50\2/ B_BJ)/H':GO'&OJ5M@SX]]X.-+I, \J2 MOJSKSKWGG/;>-IN\[BSXWE9)[:=9&8*])\2S$A3UN;&@$2F,4S3@U"V)I6Q% MET!&@\&8,*,#Z- /D2.;39XK<$YPZ#WL@<@]S:BU4C :A-&DTKS!VC=%(1AP MP]8*4_* TG"!>-9;4!>>J$(*LI6D!O;/81YQ.W:8:H/TJAF?B;,Z%BT:Q>?LN( M\S^NI;&)E9)S1S>B(5!U5J8XYHH*W5:JC7&K-V-6YVP3B*OBP/O68: +HJ5+ M,'B!J"=(_2_MCTYAQL%1@C&PPT-14@?\)3BL;_O9^!K0G8]8U_K]IZ+7H"?U MT.$E<9*/42(^+A/Q<96(C^M$?(P3\7&3B(_;1'S<)>)C.$C%R.>-2NJ?QMD[ M4$L#!!0 ( +5VK$A(=07NQ0 "L" + 7W)E;',O+G)E;'.MDLMN MPD ,17\EFGUQ2B46$6'%AAU"_( [XSR4S'CD,2+]^X[8@,)#K<32KWN/KKP. MJ:P.-*+V'%+7QU1,?@RIROW:=*JQ DBV(X]IP9%"GC8L'C67TD)$.V!+L"S+ M%4EK0VTPAGEN&;>5ADZ3SXB?078VZ:WM*6[13@2=&AXD7U(V8#$NTIO8+Z>@"%,;X[ M)9J4@B,WHX*[O]C\ E!+ P04 " "U=JQ(!_DLC@0! !." &@ 'AL M+U]R96QS+W=OB8[8% %4=CHHVQJ+VT\:X4;'_="U85=U5BY!)F8.;YXC+^6=V3?4ZHN8_%/"U0$ 8 ME(5!6130-@S:1@'MPJ!=%- ^#-I' >5A4!X%= B##E% QS#H& 5T"H-.44"I M7&A&&8>T5-9QVCJ=U35URF']S*[7+:VM^1:^*)KU-?%CP/4I4^JB85;1[#&ULO511;YLP$/XK%D_=PT)(ITF+4B1&J%(I3:)"VV?' M',$JV,AWB9+]^AE(&,DJ=.'\^?ON?)\/)@J'XY71%1B2@&Q?%@K'%KQS M &A MK>5GO$!H67_ AA/JLN+JX+:KN51O^%PE>LH)^JKSC39[S@VDMNA9]@YL.+.# M[;.HM6'.U0;2/O?OS9,7+V"P[M0;#8;VZ2PXX6UNX*E4FQ67!OW)CL8[$*3- M\9IV=.TMI5K4EXXOB3T?.FS-$>KPSMEQ([DBAZ'\9915$2 MLYOGQ16:VX\U<6)?C]'"\I?W;+F*GCZK"8-X]J[&&[ D!W;\N!HGXFU9&ULS9--3\,P#(;_"NJ]2[NR':JN!T"-P23@D$#&@P&ED]REM3/9F=L:RHVZNLJ.FYXP*65:JU MWG1CV>]4[(S@=3C)00[MZ>^?'BC#DK[R$-10U;;MI"VH+@Z[>Z3^IIEL_3;);FTU5^7AIKNUQ@=7TY&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O& M-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5' MY^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X M?+&A T%116F]? M(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D M3EJ(X53"Q,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS* MVG0T;1K@X_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3 M]WW?ZYMHG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H M0D;CZWH2%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9I MTAF6-$9RG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_] M]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N M(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3 M?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0 MKH)[ ?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO J MQ GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3- M"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@: M0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\ MEAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH ># MKU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@3 M9ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$! M=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_ M6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND M]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC? MAT6:&C/5BZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2. MX>V+OP%02P,$% @ M7:L2"L&P5\M @ ]0< T !X;"]S='EL97,N M>&ULS57;:MPP$/T5H8620(GM+=DTC6TH@85"&PK9A[X%V9:] EU<6=[:>>SW M]*OZ)1U)WK6=$)*F5[]H=#1SYHPDC^+&])Q>;RDUJ!-<-@G>&E._"8(FWU)! MFA-54PDKI=*"&)CJ*FAJ34G1V"#!@V48K@)!F,1I+%NQ%J9!N6JE27!T@)"/ MOU0%3?#-T8O/K3(7W[]^0]Y:O%PLPIOCB_LK1V[I&"//\ZX UM4I#M(X&)*E M<:GDF'.)/9#&S2W:$0[^D77/%5<:&2B*6F& 2"*H][@DG&6:6; D@O'>PTL+ MN'T8_ 232KOPP/93&G)8& C2KMG8TJK;2 ME3%*@%$P4BE)N*7<1PP&T.:4\VM[ZSZ5,^ZN1-['GG&(D56Q-V$C!G.\!FY3 M@RF;YY[0OGX6+>K* S]$D[KF_5O.*BFHU^JAM1IFC]%'#]"G,=FSHJW2[!;\ M[3W( : :HQW5AN53Y(LF]89V9KC 05<^I/"Y)?])3;]_UT8U< /_]O;\T^33 MLW%_(;ZCYPE'<=6*C.JU:\P_+^S5V?^JS+X/OR8M&/K(I%G-6M4!15G+N&%R MKX'8Q^7*ZN:S-C*V*> LNK%#N55#,GB#9UF K* E:;GYR';*N,4$C_9[*S]: M';PV!XH$C_8'6K!6G#L%XT.?_@!02P,$% @ M7:L2,UKW[E( @ @04 M \ !X;"]W;W)K8F]O:RYX;6R5E%M3XC 4@/]*)D_N"[UP41CK#$)9F%%P M+.L^AS:%,Z9))TE%_?5[4F2-R\/*4W*2G"_G?FU&>Z6?-TH]D]=*2#/2"=U9 M6X^"P.0[7C'34367>%^9IN$AI2PQJH9",OUE%G^4ZNF!KE%%B4E M:&,SYV[[L@()%;P[NU$R.[6?*PWO2EHFLEPK(5HM=]$JX0_F[PG::"'_\M"R MS:/+1$('(0)?P, &!-BWA+9[P9TGP3^NM.'_W!'9!N>88L)D05)ID4(6\I \ M#(VS 1\OBO9C/0+> M]N6I=K=#IGQCR0PDDSD6K:=ZY:E>G>O!T ,-/=#P&S:0"RQ[PF(?S?EM:L7_O('R;>JG,I]410Y,'H.U8-;47%6H_3 MT]K?H-4.95IB%+\KVHN;=T\O?L_8NQ[\/*[]4*^!UO0@=0BB'E>ZHW6M(RGR M7QOTDZF-M^]#]&>3KEK^G@BZ8_6?ZBA+M=K0]X[T1"ZU?&/]"[4Y)#K@@=7" M_'J'BY"L&2R^UY />%:M>?;P3QQ9F]N K0&/!IQ.&B)KB$8#BDVFL#*3UP\B M29%SUGNB(_IKHY62/O 3M01(\!T3T )C>1L<>/[?&]/09[;.R):WV@V((B?0Q(G(#$ MV+-[0&L4*0! L<19EL[8YM1)24V,Q40:H%@^!F1.0 9EX*P42["2&3DLG(@% M^)VU8A&+V8BE$[$$?S2!L)(9!85")\-,JPA3-35H9E050FZ*[ 8O<,&AE'$[TRJB9M77NED?0T1BYMBZQ'*N9 MDXV[[Q&T-9ZJM4$SI]C&PO=V]R:W-H965T&ULC9==;YLP%(;_ M"N)^A6/,5T4B-4S3=C&IZL5V31,G006<@=-T_WZ&X] D,R?NZ:/^N1"5/"Q?<\XF712ZJJF])]_S'-/K99U]XN7]N_=LP7*W_6G0BE]7O7*Z0]&O-CQJO.T;T2T[>C"=GJ>AS7:8J67V MOF1IYKWW[5PA;$!6!IDF/(Q$ N]1G3:SW#QQZ3@ G'J9P< MF2BE(OL3\^?X1/9+#Y..S\@YL <=8$9Q*ND,P\*+)[9E0!9JVL:>=X!!Q:G M,PRI]C3#C"F.!5WA@EX0%V>^2<&,U:)V2./84YQ*O(,\R4&GU&3,W(^ M9_$,([ ;8>B%1$\KPT0)<;OD9RB=\S9HCT^&J1=2\6F8+T' (VJY1HXE%[?O MM)$]1!EF7TB]81IF\A%EWC%'[/]'E'?Q G\H=N)GT>[*IG->I=+? L,K^U9* M)70S_D/H.GO]C38>5&*K^MU8[[?XU8('2A[.'V'CE^#R'U!+ P04 " "U M=JQ(*FYMV$@" !L" & 'AL+W=OM,=1HS ;"$VB;.^^^=/5-8'U0" ^ M[Y?G2Q0L!\K>>(VQ"-Y;TO%E6 O1+P#@NQJWB#_1'G?RDP-E+1+RDAT![QE& M>QUJ"4BB* A*DZ? +"_BI;1'[]XP)'99A'%X&7IMC+=0 MJ$IPS>V;%G>\H5W \&$9?HL7FU@CFOC=X('?G =*?DOIF[KXN5^&D7+ !.^$ M*H'DX8Q7F!!52<[\UQ;]F%,%;\\OU;_K=J7^%G&\HN1/LQ>UM(W"8(\/Z$3$ M*QU^8-L#5 5WE'#]'NQ.7-#V$@F#%KV;8]/IXV ^*6(; -@ _S0!,[WKEUDB@JF1T"'B/U/TGN>TE- M+XG)SZ;SZ7T^,_G4Y.?WBIU&"K,6!DF3S,^L+1-GTQZ9LX],%\C@=!XZ^X Z MGT>NI3;(RB*Q']D\(%Z+W&F1FWSB6JG+(*:2'I5$^8F29,9D'Q.\1NSW,?2DOQCSB:8_/B/$ -W?M'AWQ+\2.3<># M+17R :#OTP=*!98EHB?I679?OV#4?T'4$L# M!!0 ( +5VK$A6LI$N10, '@. 8 >&PO=V]R:W-H965T&ULC9=-F&SD^A?ASWGTGEOFVYX5L-=^+ ._7/ M5O1M)=5CO_.&0\^KC0YJ&X_Z?NRU5=VY>:;;GOH\$T?9U!U_ZIWAV+95_Z_@ MC3@]N,2=&I[KW5Z.#5Z>>7/?8^#G^RG[=SU<)?^E M&G@IFC_U1NZ56M]U-GQ;'1OY+$X_N!E#-"9ES?*EGE62].SG"HQM4F]PKO MQR0JLZ,&,ZAYTCE[/5-Y]I;'+//>QCQG"-5( 0B9"4\EM_9 75LXU>'T>@G$OL-)+ ( "A)+W.E,#$9(&.R*HC M AW4UD<,.@ A++[.E,!$]+:,V"HC!AD!(@.0T(\0&<#$\0(=B759$] 1WHYG MUG$PB$IZ96:4%2NQ62\ DL==C89A5E*+SDD[SLD -_>*W MY@5&P2C9@CU'[4Y)P>$8YI2&66%'T3#QDK'8G9*"Q3'D Z@PC)I9[#-IHEBZ M8,=1NU]2L+G4NILF-< @2'F!7-=A]TIJ+ [[=#0,JN,K CJ\3Q_T+>]WNM 9 MG+4X=A*^MN?6N9AZI&-!\*6]4$46E$0?:?+L4.WXKZK?U=W@O BIR@U=%6R% MD%RI\N\BU]FK,G!^:/A6CK>)NN^A,(('*0Y3G3<7F_E_4$L#!!0 ( +5V MK$CHF-5U(@, &D- 8 >&PO=V]R:W-H965T&ULC5=- MOP\'/[X/J# M!M:PC1Q*5.KRQDK6-$,EU?-?*/K1YT"\O!^K?]=VE?R72K"2-W_JK3PHM;[K M;-FN.C7RF9]_,/ 0#04WO!'ZU]F1<1+.\V/42:SY28J) MC(T3 R'^UY#R$^1+%0FJ(C$N(HL* Z$6H:6!D&A>18J.96I4Q//\#'61:7Z MOG!PD<% H3,';!C,BBY8/\1'A>AFY22Q* %,%&86*0!*DV2!%H)K,6$0$IL6 M I83"ZH$%"%T@1B*BS'!$5*;&(-9$7QYCV(,:L&,)P$N!3+(MO( 3KW0&> M;M0'(;;/!8!6MC4,F'C!F% \W"B9S_,U@%9!:AFY$E#9@J\7Q<.-4A!CBWT MT2"U9)=[&!;UN_USEXX M&W[JI-E>3JW3Z>&1#CO@F_:U.E68,\!'F2(_5GOVJ^KW=2><%R[5_EIO@W>< M2Z:$^7>1ZQS4N6=Z:-A.#K>)NN_-2< \2'X<#S;3Z:KX#U!+ P04 " "U M=JQ(O91-":,! "Q P & 'AL+W=O6CG-"\V![ D5U#EN'D[@,1I3W.Z%)Y%U[M08%7)5EXC M%&@K4!,#[9[>Y[O#-B BX*^ R9[%)'@_(KZ$Y$^SIUFP !)J%Q2X7T[P %(& M(=_X_ZSYT3(0S^-%_5>;$9) RT?I7O&Z3?,(]P&P1JE MC5]2C]:A6BB4*/Z:5J'C.J4_W[.9=IU0S(3B$X&E1M'F3^YX51J?:C9*<@=(%)Q,.,61',JU]M4=!K]"+2BZ_I MFTOZ)CG^=BD M*Y42A\/R0-976KT#4$L#!!0 ( +5VK$C_)_X4I $ +$# 8 >&PO M=V]R:W-H965T&ULA5/;;J,P$/T5RQ]0 R'=5420FE95^U"I MZL/NLP,#6+49:IO0_?OU!6A21>H+GAG..7/&EV)"_6XZ $L^E>S-GG;6#CO& M3-6!XN8&!^C=GP:UXM:ENF5FT,#K0%*294ERRQ07/2V+4'O598&CE:*'5TW, MJ!37_PX@<=K3E"Z%-]%VUA=86;"55PL%O1'8$PW-GMZENT/N$0'P1\!DSF+B MO1\1WWWR7.]IXBV A,IZ!>Z6$]R#E%[(-?Z8-;]:>N)YO*@_AFF=^R,W<(_R MKZAMY\PFE-30\%':-YR>8!YAZP4KE"9\234:BVJA4*+X9UQ%']8I_MDNM.N$ M;"9D*^%W$HS'1L'F [>\+#1.Q S)@Q*X(Y]:LM,GJ-G@5Z]C-];V6'^LT!^*9!'@7P6V%X; M,6(."^;V6Q-VMJ<*=!NNCB$5CKV-6[I6U]MYEX4S^8*7Q.&Z%;TA1[3N M9,,!-(@67/OD9DM)Y][/FDAHK ]_N5C'*Q43B\/R0-976OX'4$L#!!0 ( M +5VK$AFJ$EEI@$ +$# 8 >&PO=V]R:W-H965T&UL MA5/;;J,P$/T5RQ]0 TDWW8@@-5VMVH>5JCYTGQT8P*KM86T3NG]?7PA-JDA] MP3/#.6?.^%).:-YL#^#(NY+:[FCOW+!ES-8]*&YO< #M_[1H%'<^-1VS@P'> M1)*2K,BR'TQQH6E5QMJSJ4H#\@OH7DJ=G1+%@ ";4+"MPO1W@ M*8.0;_QOUOQL&8CG\4G]=YS6NS]P"P\H_XK&]=YL1DD#+1^E>\'I$>81;H-@ MC=+&+ZE'ZU"=*)0H_IY6H>,ZI3_%9J9=)Q0SH5@(=UDTGAI%F[^XXU5I<")V MX.'L\JV'FR#BE8GW9OW84=/$P:OR6.7YIF3'('2!2<3]C%D0S*M?;5'0:_0B MTHOOZ:M+^BHY7,T.[[X76%\*K)/ >A;X>6W$A-G/F"+[TH2=[:D"T\6K8TF- MHW9I2Y?JS)!): M%\*-CTVZ4BEQ.)P>R/)*JP]02P,$% @ M7:L2"KR-2BM @ PPL !@ M !X;"]W;W)K^LP9A''WTW ML%W<<#YNDX0=&]PC]D1&/(A_SH3VB(LMO21LI!B=5%#?)3!-RZ1'[1#7E3I[ MI75%KKQK!_Q*(W;M>T3_[7%'IET,8G/PUEX:+@^2NDILW*GM\:_UFG.LP= '4 _!*0S$(JS6^(H[JB9(K8B.3C@:V M4TDBF".1&Q/75IQ47;RN;C6 H$INDN@!,P?N-<8B$L'NE("Q*QRJ<+@P#<.KH,,]_K6U# \P/HUH&:PF< "PIP ,C<.KJP'QA0B _&PO=V]R:W-H965T5>R-P?:63OL&3-5!XJ;.QR@=W\:U(I;E^J6F4$# MKP-)298ER8XI+GI:%J'VI,L"1RM%#T^:F%$IKC^.('$ZT)0NA6?1=M876%FP ME5<+!;T1V!,-S8$^I/MC[A$!\")@,A@7NEC,\ M@I1>R#7^-VM^M?3$RWA1_Q6F=>Y/W, CRE=1V\Z932BIH>&CM,\X_89YA*T7 MK%":\"75:"RJA4*)XN]Q%7U8I_AGF\VTVX1L)F0KX3X)QF.C8/,GM[PL-$[$ M#-R?7;IW<.U%G#)QWHP;.VCJ,'A9G,MTEQ?L[(6N,)%XG#$K@CGUFRTR>HN> M!7KV/7US3=]$AYO8/;W_7B"_%LBC0#Z/N+TU8L0<%\SNOR;L8D\5Z#9<'4,J M''L;MW2MKK?S(1PB^X*7Q&PO=V]R:W-H965T40$ M:4)5M8M*HUFT:XR+5DN]#,7)*MH;4=R&", E[T@Y!69C8 M&R\+=I!=.] W#L2A[PG_MZ8=FU;!(C@%WMM](W4@+(MPYFW;G@ZB90/@=+<* M7A?+*M<( _C=TDE%5.*_3O.< M4A,OYR?U[Z9:Y7Y#!*U8]Z?=RD:9A0'8TATY=/*=33^H*P%KP9IUPOR#^B D MZT^4 /3DTX[M8,;)/LF@H_D)R!'03)CS^ F1(T1G0FPJMTW% MSE3N2Y5:4Q:#O+XMI'(R^+$-[+6!+3^%=VQ8#+[CPB+2QR82KXG$F7CB'4J] M ND3)VPQ.((PBB/DW79WPA89IS%$:82SQZ8RKZG,5?7$*Y)[!?(GJK(8E.,, MJM^=HAP09O@*:"V%%[VAIWQO>J8 -3L,TGZW=4].7@EO\S#*/W+J_LL6WR_OY].[OVYE[;C MA1_!+[,XF7L9_&=RMY\N$M^;IO>^G\W#_5ZG<[P_]X+HU4\_IL%//V8_O8TG M^=R/,NE%4SF,LB!;RE'$(P1Q)/=D>N\E?OKC?O;3C_OX#K]W(#_&47:?PCM3 M?UK^]:.7M.5!MR5[G>YQ]<=E6W9[]3^NH^<_^K=IEGB3[/^6WU0/7_EW 3X! M0YQ[<[_R\5\^#J]'@[$<7%Q=-@PQ@.\G7@C?G?I?Y-_\9?FY09XD2..[()W M<[_X7H)\D&^]K/+!O;UN;^^@V_"IG_TPW/L&D?^5([2-/>3\@OG M<<,0G^(0Y,)+ED!.Z">5E=*34C1?^8LXR8+H3HXS+\LKC_]276LU @TO!S#' MNSBI\&0\]T+\W8X_B.<++ZH\>)UX4_K\DI?R_T*F3/O#"M#&.^H4AKDC:M>.+?_JU.NP87Y^.+L]';_O7PK7S3 M/^N?#X9R_&$XO![+G9OS_LW;$?RR"UH_O+F2.__SG_^]*^$?,HCD]7V)O_""J?2_@)U+J[]? MQQDLWD1]TJO]Y&4"1C(!:4+[XO^6!PMD:TM&?B;CF?0FP.<\!,Y.Y=0'VSD) MV.[ ;\.#WJ'T,@D\GMP;Z\:&ZJ!+/P$O_/DM:$$3/T;1WB*))WZ:2I!>GT;" M :;^@Q_&1$OYE?=Q/'T,PHJF\&SK9ZG9?A9XMT$89$&56?W)!/U)*A?>$KE= M7=:9#X-,@:;0646P_O,SH67U-'! MTPB;"25%OX_#*=BV/\LA+!FLW@Z0%TR";+=*"AF)E(W$37O&'N_R"[K4ZGH_]?^3?IY=E]G 2_^],?9( 6>"H/.@>MDZ.3UG&OU[#N3UER MD%K%R95$':TB* +'H*F*$QDW&[W^=!J@P )/45?V0',GWB( 'M<(@"/JQ,U5 MC\39/4QR C8=5@/4+W@ BB+X[XKD\(JFA67SU;)-&Y:M(@7$WJ\;XZG&;>?2 M0^6X][, C/UZ U<(9HQ=K ^+"L]^)_<;HJ>"S5PS9.'9YB'[XS%,]*GFKM'. M_3]DQVJE,D(K=X!MTS@,O00T'J2#*-N%,9K)_$Z"W*\>OR+_]!W^ZQI]5Z\J M35GQ6D4I_]"D*J-]U12:WOZ&6:@W'?NPDG>NPHROX7\^#L]!62[>R8O+X57_ M>@0/R/[Y6PB6/UY>#3\,S\>C3T-Y=C'^]G#!U9"*K;QB7U/]<[VKE*F?/ 23 MZH*\KW53;&22^F\,&X**IF]7/NE'/B8-Y!:F\R"B+"0#,UE^\HT7?98SO\;C M6CVL_!; 3UF,9A#>K!#Y+D[\X"Z"R&AR[T5W/E%!%KN>!TT1U 4(O$?!^\Y9 MG*:[D +56?A1E/D@4)D>I_P[OBMO?.KZI[3;..0<;*4F#>F(5M";_IKGF9U2SU8._ ;+PTF M$N0F EXZ9J2ZK&&.)GC]DRMT== ??Y#OSBY^_G:EQ$ )HTF :!:%/PK_OL$QZ:UG*(URU/X9X!KNI2Q^8[7^!U*]V@M M@=^\,DKJ8(;Q O]0G0XI08I3=CY!D3)IQHIH$T*>)"<*6<3!F$;%F+96V.HD MDR9NYVM8\,2)FS5)>5%&$&.G:Q;E,@=+Y0%K(%U9U+K^1D(5G?!_^C-/)^U= M$'FP^"M)JWQH9EYJ_M!P-@.SATLP*ULXX)^//TQJL?WR+_H!W'9_46&4L#FD8@WQE*J3[;Y^Y,)SQ#))ST.YFKIP(YH MAL+'9H9WJ>4=4/1Q.[4+H0>1D]Q+4WP\B<>^! M,[CU_0@TSX=PDC4]T0 ?@C98EC'UR3S8>& M6O@QZH7PT-(U'@Y>[;;% !3>(R6V%5-\<1;'&:Z#G ;I!(QSGN"Z)%BR6Z*' M#O-I02F++#'S@0>0NP,%,TZIS?SH.,2@8.P](<8C"89CW76 758HLG+S9(9![".L%: M^!Y*WYU/H0--#.B+PYU1BSI5B>3O**1C%:BG: M,8A%YK+;V?L;"3F^,^-BY!++ECYI1Z764"/P34+M"B*J3!ZIN;7EA_@1XMJD MI8F-%Q"]LGEQWFK1?YC7"MP5M5^%)U :X5E6$?T'"9+AA%:I?QWGU2Y^9>U/0 % H8!.^FMTGOK\WQWT, M;1]\3II*I9Y'()^J@TIIE/1AV$A+[F6@4&UC-T2SW4#I?J6? RORZ &;0/9( MQM2Z@]0O8O;A?G3GW;$9@^QT M[2;ZP;ML6(Y@B/FD?\&9HH8XJMORLHWH3V M.QPE75".9*Q'A@2Z2] ?O1W+AR#)60> (UX2> +_':(/$O$$HS1/VW0N'JD9 MI#13,%'@V@.P[VB4? A:0!T#M"NL4A"PI('V P4>!J*/9^]+NGQD329IB^ M,N?TH" %J-Z7%%Z.: GY>=>P #VI[W^&^0@L]X(32/%[\$%(HQC0X:6Q!D+*;N MW>=S#QUU,,_C)YJF//LX^D3_LO, M; 8IUT.)"5: IN1GLWN8-UK]$D#O%/!_^-P#SI"?O4,P\ ^V9 M^PGZ%:#X(: M!&L*5N L0/WNV+'=^F$ !*AEQ?@0>;TDJAIE%"HN4EN^RQ-TCJW2N@N]C>GNB6 6A%XZ2TN[G+@LP\-> MZ_#U,<@<7[+( M8;RD@ATE1911!)Q2)1Y$&/#J+5;%R?%,X_P6F'<; Q%QGDB>$\6?6EQ$G;A< M7HW.!Z/+LR&EOK8HIW/?]:*K,@.3..1U\7G$BXP4!]/ 2RA^\NKH:C]^=B<'-U-3P?_"*OK_KGXS,["TV' M+H?Z*3G-89[$#64T;2-=BK4CYTK-S"E.\]]OP2&B %)SDD26M:7: ."IZ"HU M61=#RU2_[Z&MOZL97UGQ.%>!!(7V;4@](8X-:3?F#J+D%&-QI=9DRC,2&Z<$ M#%0DODK1R,* /*1H;O"#R'RP>!P4UVV+@AS:I:A\T>/2N$D2[QJW#X1A@U*W M@HP5DSQ55S0)<7T]&R+NF'PG%FU!IGYG:?15L6WFUNS!''AYBOIHQ9-=KBK[ MBPL!(CC>D M. >4/Y^HE ;'6L!Z4*$<"WIB"M]-45[);TW ^I%U8G+1RJ8LT1%62J:VO'0U M_#0\OQF*J^'@XOWYB!1F^ 56$===G)%C! I0AZ:@<2B@E&AP3._1V/RP\J*^ M#12D+9JX-J+ZAJH>.3&"S3?(T(LYV&LO3&,S4($8W9!!RZ>#"\N^#/F.2H,E M)*S'H'&^]\*99KH3\CRX_Q4GVLL 5$^@S'S1)6B?1,"PE/FWS'XQJPB-;EO M\]AM^5[SIR56L-&4',]^#!P4?PCL7/Z@F:\9M MZ0(^.:T\E,?OTXU$[(R M*AW@9<3L/KD+J!CN$J!R.FJPF00+?(^B^U_!=V5@(7P_82!^F%VF?*%6QIO<8Z!,X2]:757M MG <@UEDW2XX&ZHLX-S#IA>JXBZQE!ER^$]%#'(KE+@Z M!;$0HEL!/*1?? RW VQORI!%27!WGZ7Z)YA=M\.)B/1F." 7]A*PF/;C$M)P MOQB*H@8;>4/M)GT!WQN@(83XR+3'4 SD%!R".;ZG5('210H7'4U*"S4P6*0: MQ49_832J0)J8QCYG7E/:DPZ7O/!Q"$OLNC4[9?1IG;V6,31I>,DWEFQC^ M1^Z\ZX_?[-8_,8BG%/QQ4;$_'NS*ZW@13,1QYVBO=]22KU3L!#$430@?_.?_ M_XCIR2+T]X8A>YE^DF"01!QKO2*%@<%X+$ECG3:.I1=$?/0AY)["ZVI'0%&K MM+E@CMMR!(J3H/\#E5$/USY97+(Y!"L2Q!]&GBW)VA67L>2'FRMQNI+QYT=7I5 +FK[0QH;98C&=2+)_'$XZ$P8RS M'J^:A\G^I+=8@,,D#=(EC\2N<&%N@I[E,,'W4&-G-1^"9,*COA2IR=559*!3 MNP">@1O4%#Q,T0Y,O(7)*D3%,-D80ZH,E?,V?-#:0%O_QFP^P^1/B8@.L[D@ ML0@]R#^NQI\*%?M1),Q&"R3/!T6YI#(P-PC$E/$;H2,[@44B9S VG?89TP10 M>DYMICD!HF@.]_!=U^([^J6\-==^'>]&+#<%V-048+F(#_^,J0ZFB]!MX3HC M(WN>O!E_=X2&.21GN8"\"2?%!KAH-FTYU?_B3W+7?Q;UM!!)804&N_U#?RJX MJP2_;%V!=>6+&/TM5P8S;&I"X?GNY,10MP ^*A]!"6JD*X?D;L':@%+#-TN; M]Q@U-U%AODW>IRE(I4*M5%,Z*7 4VT*&_LHE/0KJ50V663C);!2<0*UE5%6;9*5EYW MYKE37BMF2[3=YL2/G)'@""7)-\&_$J/&-3%QN+75-EI&'Z\"S+]2Q#RHU'3' M.H8>F!AZYZ\#\,%%Z7%IUJ7LF[&;0)$H )]!)'=L@'V;A/%D(+@=;&AA3*W104TBPO4QHR M]PL2@Z'0/5;92HZ#0^NID7L==E (CNM>3>61'AL]E9MFZK-SG9IZ*EML]CG% M9,:AL+H"FE:U5ZOK)D5],Y2VY44D_@I&&?L8T&I2ZX#I)3).%!(1Y!?I>GD] M<2<4 GN209V?1+$$$W$'_IU8X9<] 3>,-UYOUZ M9XN>5<5L8Y\-^@['T9!SG&SCII.6BIUN_>P1"]!U6_@HOCACGNA,-R3=\BIS MN5KM9_PU#RU7(>H,OH#-8LG3=0?=%.3X@*:,5OX,XB=4<9B^BWY/5>D@/__B M3V5Q<+U)D= I35"+I;6=+7M&"M6/C)I],4A=/>!OH.#C?AP6/_FLCD,&:Q(; M3B^).*"V3]N,05,6I[ROD"C0?],8A=F_VKP08[.Q]>CZYOK(49U8VR^TYG, MX:I,QA1C>=-@AM,MQ.FU4Z=0L;%?0IA^B88\*'U*KP77W+ _CRP=O(K.U.FY M4!O!,79-&0?V!JN42/=',- 09LGWRD%B/;B8H!COK+;_9D$RMR&'"1AN53.; M*BT76DA2,QHX,)U."?:;'T:?:CH<:OJ!T$).U1C38 9+X'.I9.XVAYIDK3)Z MZC90!)%P8Z'ZIA?=6 I3TJTSMN'$SS!@*A'*<9(_E6:O49U M:5UU(TK&6< M!'=!Y-3_(=XJ[=QC2'7K33[?46.P'%WBUF"A[\^(09T$UGV9DRI=1;'-8^"D M=U*?^Y11#W&S":N5:!*P"R[=;0AJ;(!@C'JSA=/AD>G= >4\QSIMO6XJEUJM M+^#[\J-J)5+M%S 6!-ML$G=@[%T38Y[I('K)/0'\VF@^SSE&( 7A43AFV,%V MHEW-XW-/N2?+1?BEC^?\[WB7>F1#A+>ZBV_G?-0?O=W%KB@,D$P$=$]Q'1E< MEA]AA*DDTUI;"J*/OK6^BVJOTD5E],#9>+%![",6;K+@#LR]<$]EX-QYK6L) MH' OH[B5-94:$((Y]1M!&)BVU>K ZLZXG9T:76T]0,M)D&KQ;0DF$%+!1 UI M0LA.]TAE3]/*+\=5\U$(95?)I>O8A);+#Q=7HW^_.!<];%,!V33:44K_*=[S M0VZYG!L%!" *WY@^SY+O+E/<0]M<'ES>B!?(-G#@W;7 M?!8^@I^EQ);;3 IB@9\X:;5GGQ;IA2-D9#Z] M+74=AT=C@:3=?%B9?"YURR17W[B/# GC]$/5L^D[A5BG4D+%MG%_#R:JO$+MA2\'KR/GD+N7OH M+JK9*?*R+ EN\TPW%AG;8)6D93PI)&?8S&X5X6X<&P!7.$=:H65QFJO M'T@X[,DY7UA#.V=*W>"WC]Y2'NIN^A'_-XE]88O7*8%B0Z.N>)J"#=H46C#* M]ITS/-IN,8.XS(-BWVT?67U@HNVPH,Z"@AHWK5<# J_.1N.I7/G!K6\4%.)[K,)"O<-Z%,>,!FU*,5>1HR:?+4+ MAL$ZK(-3HT_LASCDY=Z<8**B770*IJR4ZBT+T'94-MU@HHN;6+-X1 J(@0E[ M>&PBTW]WSA54KV^ 56DX3F$V#4$9[JBUJ4BX$C_[&:IE.+UJA1EXG!+IUZ5J M6U6\P?)NL2*!.[]H7F@'/^7S/TMS'-%VU:IR50K:C&UI>&#[^A>!A[6'?[\9 M7>+I4*E/_XO"$4"=D;)@<:+%MC.U=P&@7^F=(WE D"=<*##/KL%%9PZ'PF^!4,>;'G A+R6[U%1M)"/7N<3]+Q#.SW M=[K>IJK;S3TA@5_7Z= #-U*&("\1]X^I#E[@=MO.U?3Q%>BKI8KZJ?@.$6U4 M;(?77JCB:; /=W0!# ^LNS#YOY0IK[YG^RW41,D?8S\FS"F.W$,G,%*L)+.1 M[:8%]*WM<% '@[!8%">%(B5S,MX14">P3^YW=:3NZO5Y$A M'7 !?89$DEUTE'/C$K8]8&_Z+.$4 _Z&^U"<:%!OE#VZ/ F223[G?@]B.>[^ M^W9G@8@!)P(*B+4'_AZ:]M''R_[H"O4!FU3/+L[?R[/1I^%;R7>$R+,XNN,) M"9Y0J]B=TW!TN$4SQ#?2M#I'-(+89_\UONS ZLH:FMT%$% MSUA,Y^.ZN!]$#W&(UH3+7%H$RI]@"X[;:O[$HP7#\"^E[0V<&2L,]43/J*=# M=\JK>-!3?=<4,'!L1E2XGS*NWDQ&]V^S;7&_*)[\19/9E;YCO(K9_''8U7)9 MY7\)J+C7CYR_"CJP#X.H@MU4U[QM+Z29!J;FY5EJ3V'-9 N>"2>J$Y[3>W7< MI,)C@3,V"7*!+KY(X-$>TC21#19A_$QWJFJOR(?XC(8X \43\*0P[?<7%V]_ M'IV=27VMEL[ RJ;?3%S;;%7Z,@4YQR7 4TA,R:2VD*'(J<#ZV;;YKEHR86S( M#[B%0RSZDL14[*QDFL?G-5&')G"'*"+1LLYRYU'+RCBA2_KC59E :* M^20#'U!5<1EQ@G/"+C7%84<(^N46"'*(G'+4OMYN.5] K29/1:N"U6AU60BO M7# O=<,I2E/Y&Y 49%SIT)N(U/6@ B[3@<,L)%,;!I^Q#QF&IHL3)3? S)/.?PAMPBB(U7$K MU:+5$[+VB5)V3II"K+4;AQYF)Y !^HNRR201NE,BP5DG]R;2P^BB@D2%X>9( M@,OMJAJ07!39"$L9*Y7*] :!^SL==BD9:&THRS;%B[0\\3T@:,KL@E;&-7,C MB7-\9+GQ1-"Z*)9QW!UC6AWS-K<7A&AR'(=NM%"U,O#SM4]8IZ0V6;57,N0* M3:[#RRS6[15!5JCM4 TC*N1XM0>0 .XT M5<.)@MEKX;^;F_^H.J=6QQ!7]$].+Y1.&6W,+IQ3S11&X!$CW C76]9!'46M M)O[46"\T$^!8R5MY43&?$>O6B?I-JNI=;R3O(01U/U.BKX7M,PO9TP/8]2]9 MHVE N^-@W$S3CTE_B*":+,82\^_:Y/V+BG0VR(YY1XL/[A MT3EK+RO:9+=U$Z8V-6FM]\6Q"L*U"OAM>V*68S!\' -'RD@F?)9+>7.;D)8K M2Y5[+>KOG0"_!J,G/GPHXE9@)8/4BE;__;J3NB&WF5-P2X:T,@L=?V1&%/T( M/##108<%;#)"!3OX:.@]4L"2F/TX8>M]"[HXP;,KH1L&6\3$@@GF@U)T15FE MU2Z/)N92%G.JBDX?D4ARJ<-9%:&ZW>CO?*C4>9$YZ1913&6(;\2)N-W1$EO> M__:*)]>"TE5NPMP(,T7%:MJ#Y(QA^(EK(L;Y8#Q:E3+^_2M-74 M3Z2V/TY"7''_I70TF7W8GJ%7:4_L"*Y"J+G08/ 960G<1- M'8BL; Q,U+6>S@6P>BOFT<>*!\J:.O\9Y4BC4.=Y]%O%6S +"2*VF#3=NT>* MEW)/1+$#OWGP'3U+P9;\MN'V/]Z7=1N7IT@']]+IBY[:>!,0$0MQ3H)7CJC% MJ+E^F+?GU"5X9.LGSDW,4_\VXTU+5-'RC41,LSG7-&WFB#Z%R7L!ZI2HRODC#"GXZ.7K>.NX>M@][K&G-DCK0='71: MG0-^S(YL!E(#.Z+!6U+\:,^ M!%/QTL?^?BUDZYA]]-+,/GQ]V#H].6D=')U6F'UDF7UX?2.W67Q7\AEOQWLWO+H:OA7CZXO!WRK>T[DBN'(#.)^<=6_XE>I:!$YF M^7Y@VEOA:T]2/PET*]*#QS$X65T?#[HR!S##H)D_Q-P/30<6V_(\=C^F[B]. M&FX=?_)^&DUZ[TU_# S 2X2'YV.^9F#@7.@I: >*]DE#=7&XVG$V)RZ"4A.R MW9DAMN_1KHC-54KE(U5B2Q43"Y>)XK<%F'AJVC/%/8JS(5#Q];Z5<1VX@"0? MJF^QZ!;X$AI]V*"XS\8V/6 M.<>CU'@)D>\7*4E0LQ-K_->:6+SHK/EA4=3*-F-RB-I+6CD'9#*'O5.^QQ T MN7P/F_Z OL=MC=-S8]*6ON^I[.,*=\?96PCTF<'F.Q><9M#A^'KTL7\]'-/* M\W4SQFLVW/!!381Q,L?\C92Q&(W6W(Y8>XVBS?9LEHOIP1Q"%*,!ZJHDO/U& M&2+>+6 W;1-VWUQC0+N']44CRG?M%9$DWD25O6I&5-XI[DM2T6#5;8EUY)B3 MMX5K/QP1L;4RK8=]OM5(=V=.*![AKDF]!TV7PF@V07S1'UV)3_VSFZ'\..R/ M;Z[4%_AO%,^EWCZC'<: +0T5VB*( ML%)SX2WOK5!B6#14>+U&@(&>DM_OQ1G6'$1W3_Z=[(50AW+HM"W)I[Y0B6H) M=")K8L! **BV"]16H_7V(/U&@H23(]-/LBO-!6'Q+1H-WC7R WK0=.^02=#_ MU3*G=UR;5CR!4DO/#Z+X0A"9V1@J:'.59OH#>1ZNZ3,[:TBE70?NSP=SF\34 M],A)A_,0?T6 H'JJ4=^Y583E-L<*HW,BOG8"BI\'>Z#6=GA1)B_-%TK0ZW8M=Q^F):M;*D;LOF,4^'2;';(NC!HJ\Z5 MT=B:50?$*M@79? X$:GL<"D'FD(\E>W1*O(1*\6TU+%+PIG2BJO8N+S)-P?0 ML2Z=GFJKTK \10R MP_]:Z\EFCTM0JF?U/EBP \*CL\6S$ZIEKL$/FZZ)1C=Y0P0=U+XGG??*5Z]=#<_P.GUQV;^Z M5I=@]0<*]"(2-J;2\;SI!@V]1TF'!%AKZ>A189OLS\;)HV,"9\8;KN "=+Z$ M#_.E#_ ?!MVA6%TSJ3/(_LQ/4W6#FF][T-3@=*VP)DF?A1XR6X8G]F)9WAZG MKS?'?V)%I 4AZ/!GT1\,+F[.KT?G[['Q[!S^?<"N5-C^2=7/_C777JAPMO;! MFP7%%^=QFP;?Z[QNZ;O"2.R!9_HH$LG[((=0?PX^]7MSL\4QWIIQHU_?;?&E MTL 3L!U\AUVX5)7E0!\5K5Z18"($+F>\[_H G#K1$RZX6NS=(QBXF>F[YSD.(HH?8'9B'?S77OE^I7;-%26SCG M0K/I;&4IP9BI0D6[,!?JB:*X:$:E*]SU507+CY0[%3N"NE<=8HSC$O\;*9)<;U M\ ><9Q5:2'LO5PZPW(N MBN/4D+Q@<;NX^I"^F4.?\A;U)+?+DL@E/.I1*%XUS@WT?&&^W>;3&9F]/9JO M,C)FN,O',D\$]_FHL!'-S&.LJGOI]P(OR$K\+(FU.1&:?N[,*W_0WN3MG-1: M: [2$01S*8MVS[PM- TXX4B5J!I1%(RZ%R,%ZAP MT;3:N+QU=^6+69%Z45_ 8KHV^9P!W7O"4Q'.79DV$RM,!BNSSE?=^*5XZ;$^ M,: $"+<^)V:WV'HJ??V9-XW-=0WNK&+5_++N:LMV&2*BAQM^IB^T'@*R\D + M=S7D#MVJ1V3IEJ7=%; 67_,9%3N33E+O'RV/,1>-YT/K$0"K-:\*4FX;'KK- M+$A*%?<)?GUKL^[F::X>9V"407?H%[9/:!M7%2D+9QMH[X%/HI10''=J !_P MS1O(4+!19F"O,!O$UISQ,1F,:R .?30;'Q284WHE*I]JN?W+^K1$M9=R>'C0 M.NF^=BVVWC54439W>HQLN[P*H3@Y2-7G1/D>7W-X M3/-J)83KH (ZHCR+FL MPDQ&*+ 3+)%@C5EUS)J[P2HR]+W@D^P#4YN55VC)SZA@)[MIMD=PP/+2D/)6 MGVHQD[PD;S"\N=J_&4,T2_^%X+"RSZYHYQRHVJ6!Y0Z?[=B5]HMB""%6Z"_- MR?Q^^WU;[G1W9>=XOW= H-%R*+O')W*G)W=EM_,G"-WE=[+3[G;D^7Y?]*.[ M,):C)$CO):&;X9[GS@$^NM_KX@ G,,!1IU,9X*@CN^W#SNN.N**#GD.<$[ = MRS]GV11QHO=Q$!ZAVVH>X[#WNFF,#I#0PS%.UXQQO&*,P_W>D1ZC1U7ZVC&. M3D^;QSC>/^@\@8ZC@]-F?G3WNZ=VC%[3&+WCH\8Q.KW]SFL\NH=']2)6&*.[8H2#3D=\PK-:_M*/;O/D3G9.]SL' M^M4Z)O"+AYUF1G;VNW8$NZ!'9HC>$0YQ>G2X2C9/[1"]IB$.#DX;V0CS ,GJ M=+NT%)TCT+&CUG%Q+IV#0U*S>B:Z(_2.#U>\WRQ2G5,]PB%.HN;];OO@Y/2D MGH3" -W5 S2+)*EYM\=\:!ZD=]QI8 0,<:B'Z*T>H%G)NZ_U$ >]7M,0,,<& M&MP!3AM)Z#:+9>=(+2>.<+ABB*-> PGN -W>R@&::'C-RK6&D[VCD^,&&MP! MCE:^O\+,'=H1&HK'(69H2#.M6V0S#.ZYA"[FNLA=L LJ_VW89X2]/)\9'0F)-Z_Q[M86K8,*NK+H PYH["FJ#G-WKM73%_I_E'?'H)2)Y[M #QX-P1(\;KY0AAY0(T:,59P)I?>0#=*E6UP6TQ40(MA63LW9 M%WQ'/8K[PTMN+\8 ^,J//#R#\6&YB%/J$=3\HCCY/9V9HW!9;7QDZB)ROBT2 M>V0:A,'")<%FB=%&7?A5+I.: 8'DU=H[XNS.S*N8C-B%:M4@815'J_1T$?>7B\\[QRZW> MM'^7*M:YHST,F2=#2C]H'B*$7VT;#J=%F?"'F6Z&7_7HT:C%A9YJ0BFRE5J92KSU@?X M^ ZH(@:KO6$EBAT,.77AQ&W\X%=*(G\(,57NZ'^K )H3)JDL89+60:!^!40I MJN!S0Y06$2-70)36XRK&WPA16@>;U !1*C8%42K7092*EX$HK6O"86D0+P%1 MNAJ/5KP 1&FE6:H,42J>$:*T^/T5$*7VM,QS0Y36?[4,42HV"%%J'%$S1*EX M*8C2%79#;!"B5#9"E(H7@2BE?Z^%*!4O U%:Q)JS$*7BI2!*B0--$*6B3&&Q M(^@9(4IE/42I>$F(4MD,42I>!*)4-D&4BA>!*)5-$*7BI2!*Y4J(4O''($KK M3HN6!$$Y_$U!E.KFL740I6)3$*7RB1"E8C,0I>[5APT0I6+3$*5R#42I^":( MTB=$%NB^Q*8A2N5ZB%*Q,8C26DC0*D2IV!!$J7PB1*G0V=HS0Y3*)T.4\O4B M&X HK1.7*:R#L^T;HY? M#V\JXN>%-RV>E$+59X,W+0COU\";BF>' M-W51==;#FPH+;UII!^J//U3^AC;T:>"GH@Q^6AY+8:%*!PNU_,@6&G4+C;J% M1MU"HWI;:-0M-.H6&C7;0J-*AUI_"XVZA4;=0J-NH5&WT*A;:-0M-.H6&M4( MZQ8:E=9]"XVZA4;=0J-NH5$UD5MHU"TTZA8:=0N-NH5&];?0J%MHU&@+C;J% M1N4RVA8:=0N-^FS0J-5&!X.46OG)O;AP-7"JV#1PJEP+G"KBC0*GVBW%>N!4 M?:9H,\"IDE5L$)*5Q6(-)*O8 M%"2K?#(DJ]@P).L:$%BQ<4A6N1J25;C3>'9(5KD&DE4\(R1K614T0FOI[_++ M//P^78#?^\LK\A?)@__J)POC*E? N"*S-@OC*M?!N(J-P[B6!ZK"N(I-P[C* ME3"N8M,PKK9)LP[&5;P$C&L]2"O6S<5+P;CR_1M5&-="TK81&->*45?&5;P4 MC*NLA7$5+P3C*JLPKN*%8%P;Y%^\!(RK+,.XZCQO@S"NA>K>.AC7HME[7AA7 M]^1W XQK&>8T>#X8U[7KA+TQXJE&\AMA7"O6J 3C*C8,XUHMUSPM:[UJRF>J M(*_"!7FMG"A#S%=I,%]7'3A; P$K-@4!6X'D7 ?" '+V_W/ @%;.>2G$&&E081]6N;VI@$E MM00;*S8+&ZO/.C7!QNI.J$W"QLHUL+&T>)N$C2U<_5X/&ZOOY]D(;*Q\"FRL M:(:-97/^)-A8L0$D4^>M=;"Q8A.PL;RH7P$;*[X5-G8ML\7&86,;F.W QHK- MPL8J%5H!&RO^,&QL=5]*H<@RH.JJ&',-J*R(-P4J2WQ9#RHK_C"H;'GV#L:L M=#%F*X??R["O*R%GQ68A9^5ZR%D#=4F9^5,A9\6&(&?EUT'.BF>&G"UIM(*< M+?)U!>2LV 3DK'PZY*SX"LC92H"E$6CKU/ZK 6G%,P/2RJ\&I!7/"TA;?>=I M@+3"'HWZ(X"T)CC\:D#:RC4V_=&5K.+3/BF:?F?K.T_#L!7/CF$KZS!LI<&P M=>!>OQG#5AH,6_DOQK"5_U(,6_E,&+:RA&%;(>]?@&';K!7-F+:KXJ$G0=R* M9X>XM7-](L2M>&:(6_F5$+?B62%N*W2YU%0"LP+B[=.J!^X2EV!QQ>9A<9M# MA7(6M&%87-D BRN^'1:W6D\GE%Q91#W^6C1BZ3Q/_9J!=L5F@7;D&:%=L&FBW#"D;%\ JQ>:!=O4N3!/0 MKG@)H%VY&FA7>)L%VBVL5"W0KM@HT"X'$&N =L7&@'8;2"X#[8I- >W*KP/: M-?3_2X!V92W0KOQ7 ^W*/P2T6[RZVP+M"M69\;) NQ6(6;ES36Z^@I RJ *O MVA*RDUH[(?G3'-(6QG0+8[J%,=W"F&YA3+&UL4$L! A0#% M @ M7:L2#*=])4^ 0 :0, !$ ( !X 4 &1O8U!R;W!S M+V-O&UL4$L! A0#% @ M7:L2)E&PO8/ !X M;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "U=JQ(:DR6%G4" F"0 & M @ %;$@ >&PO=V]R:W-H965T&UL4$L! A0# M% @ M7:L2)2=QPHH P %0X !@ ( !!A4 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ M7:L2.B8U74B M P :0T !@ ( !71X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M7:L2&:H266F 0 L0, !@ M ( !:"4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M7:L2/_6EP+(,@ M#_\ !0 ( !;2X 'AL+W-H87)E9%-T&UL4$L% 3!@ 4 !0 /@4 &=A $! end XML 23 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 24 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 26 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 11 99 1 false 2 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://mymetics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://mymetics.com/role/ConsolidatedBalanceSheetsUnaudited CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://mymetics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Sheet http://mymetics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://mymetics.com/role/ConsolidatedStatementsOfCashFlowsUnaudited CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 5 false false R6.htm 00000006 - Disclosure - 1. The Company and Summary of Significant Accounting Policies Sheet http://mymetics.com/role/CompanyAndSummaryOfSignificantAccountingPolicies 1. The Company and Summary of Significant Accounting Policies Notes 6 false false R7.htm 00000007 - Disclosure - 2. Intangible Assets Sheet http://mymetics.com/role/IntangibleAssets 2. Intangible Assets Notes 7 false false R8.htm 00000008 - Disclosure - 3. Debt Financing Sheet http://mymetics.com/role/DebtFinancing 3. Debt Financing Notes 8 false false R9.htm 00000009 - Disclosure - 1. The Company and Summary of Significant Accounting Policies (Policies) Sheet http://mymetics.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies 1. The Company and Summary of Significant Accounting Policies (Policies) Policies http://mymetics.com/role/CompanyAndSummaryOfSignificantAccountingPolicies 9 false false R10.htm 00000010 - Disclosure - 3. Debt Financing (Tables) Sheet http://mymetics.com/role/DebtFinancingTables 3. Debt Financing (Tables) Tables http://mymetics.com/role/DebtFinancing 10 false false R11.htm 00000011 - Disclosure - 1. The Company and Summary of Significant Accounting Policies (Details Narrative) Sheet http://mymetics.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesDetailsNarrative 1. The Company and Summary of Significant Accounting Policies (Details Narrative) Details http://mymetics.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies 11 false false All Reports Book All Reports mymx-20160331.xml mymx-20160331.xsd mymx-20160331_cal.xml mymx-20160331_def.xml mymx-20160331_lab.xml mymx-20160331_pre.xml true true ZIP 28 0001354488-16-007347-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001354488-16-007347-xbrl.zip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�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